

PROGRAM GUIDELINES

Consultation Draft - November 2024



Australian Government

NATIONAL
LUNG CANCER
SCREENING
PROGRAM

Executive Summary

The National Lung Cancer Screening Program, referred to hereafter as “the program”, is a targeted screening program using low-dose CT scans to look for lung cancer in high-risk people without any signs or symptoms suggestive of lung cancer. It is targeted to eligible people aged between 50 and 70 years of age with a history of cigarette tobacco smoking. The program provides free low-dose CT scans to participants every two years unless a screen detected abnormality is found.

Lung cancer is the leading cause of cancer death in Australia, claiming more lives than breast and prostate cancers combined. Australia has among the best survival rates for cancer in the world, yet most people with lung cancer are diagnosed with late-stage disease (stage IV) (>42%), meaning that curative treatment is not an option. Only 26% of people with lung cancer survive five years post-diagnosis. Lung cancer also disproportionately affects priority populations such as Aboriginal and/or Torres Strait Islander peoples who experience significantly higher rates of lung cancer and significant differences in lung cancer outcomes, with an 11% five-year post diagnosis survival rate for Aboriginal and Torres Strait Islander peoples. Disparities in smoking prevalence and lung cancer incidence, mortality and survival rates are linked to health determinants like cultural, social, economic, and structural factors. Indigeneity, race, ethnicity, gender, location, socioeconomic status, and disability, along with their intersections, contribute to discrimination, increased cancer risk, and unequal access to care. These differences highlight the need for targeted, culturally safe approaches to ensure equitable lung cancer screening and health outcomes for all Australians.

Lung cancer screening saves lives. Screening helps to detect cancer at an earlier stage. Earlier diagnosis can improve health outcomes resulting in higher survival rates and improved quality of life.

The target audience of the Program Guidelines includes all health professionals involved in lung cancer screening. The guidelines will assist them to navigate themselves and participants through the screening program. The guidelines may also be of interest to screening participants, policy makers and researchers.

The purpose of the Program Guidelines is to guide the delivery of a safe, effective, and high-quality National Lung Cancer Screening Program for the Australian community. The guidelines will help to address current inequities and ensure the program does not entrench further inequity. The guidelines reflect best practice and present a program that is firmly grounded in evidence and facilitates culturally safe and equitable program access and delivery for people at high risk of lung cancer in the Australian community.

The Program Guidelines include:

- Steps of the screening and assessment pathway, including screening participant recruitment and eligibility.
- Information about providing smoking cessation advice and support.
- The requirements for shared decision-making.
- Information about the low-dose computed tomography (low-dose CT) request, scan, and assessment

- Evidence-based recommendations and practice points.
- Links to existing diagnostic and management pathways and guidelines related to suspected lung cancer and additional findings.
- A focus on supporting priority populations: Aboriginal and/or Torres Strait Islander peoples, people living in rural and remote areas, people from culturally and linguistically diverse (CALD) backgrounds, people living with disability, and people from the Lesbian, Gay, Bisexual, Transgender, Intersex, Queer and Asexual (LGBTIQA+) communities.
- Links to other information materials supporting the program.

The scope of the program does not include the clinical investigation of screen-detected abnormalities or the diagnosis of lung cancer or other conditions. Therefore, those with a finding suggestive of a lung cancer or an additional finding requiring management will be referred to usual care where optimal care and relevant clinical guidelines and pathways should be followed.

DRAFT

Contents

Executive Summary.....	2
Contents	4
Introduction	5
Lung cancer in Australia.....	5
Why lung cancer screening is important	5
Purpose of the Program Guidelines	5
Scope and application.....	6
Overview of the program.....	8
Program outcomes	9
Screening and assessment pathway.....	9
Target population and eligibility criteria.....	11
Low-dose CT scan.....	11
National Cancer Screening Register.....	11
Navigating the program	13
Program considerations	13
Promotion and awareness.....	21
Healthcare provider roles and responsibilities	23
Program entry and recruitment.....	27
Eligibility and low-dose CT scan request.....	29
Low-dose CT scan.....	41
Low-dose CT scan assessment and reporting.....	43
Results and next steps.....	45
Key definitions.....	60
Glossary	64
References.....	65

Introduction

In July 2022, the Medical Services Advisory Committee (MSAC) supported the establishment of a National Lung Cancer Screening Program to support early diagnosis, increased survivorship, and create better lung cancer outcomes. On 2 May 2023, the Australian Government announced the establishment of the National Lung Cancer Screening Program. The government considered MSAC's recommendations, and the National Lung Cancer Screening Program (hereafter referred to as the program) has been designed around these recommendations.

Lung cancer in Australia

Lung cancer is the leading cause of cancer death in Australia (1), claiming more lives than breast and prostate cancers combined (2). In 2024, it is estimated that lung cancer will be the fifth most commonly diagnosed cancer in Australia (2). It is estimated that about 15,122 Australians will be diagnosed with lung cancer and about 8,900 people will die of the disease in 2024 (2).

Australia has among the best survival rates for cancer in the world (3,4), yet most people with lung cancer are diagnosed with late-stage disease (stage IV) (>42%), meaning that curative treatment is not an option (5). Only 26% of people with lung cancer survive five years post-diagnosis (2). Tobacco use is the leading cause of lung cancer and of death and disease in Australia (6,7). Seventy-eight per cent of the lung cancer burden in Australia is attributable to current and former tobacco smoking (8).

Why lung cancer screening is important

Lung cancer screening saves lives.

Screening helps to detect cancer at an earlier stage (7). Earlier diagnosis can improve health outcomes and is associated with higher survival rates and improved quality of life (9).

Early diagnosis of lung cancer will reduce the number of people requiring treatment for advanced stage lung cancer, when the survival rate is much lower (9).

Benefits of early diagnosis

When lung cancer is diagnosed at an early stage, treatments are more likely to be effective (9). Early-stage lung cancer can often be treated with surgery to remove the tumour. If the cancer has spread outside the lung, which is the case in stage III and IV cancers, other treatment options may need to be considered. Treatment for advanced lung cancer (Stage IV) may only focus on slowing the growth of the cancer and improving quality of life (10).

Participation in the program is expected to increase over time as the program becomes embedded in the Australian cancer screening landscape.

Purpose of the Program Guidelines

The target audience of the Program Guidelines includes all health professionals involved in lung cancer screening. The Program Guidelines will assist health professionals to navigate themselves and

participants through the screening program. The Program Guidelines may also be of interest to screening participants, policy makers and researchers.

The purpose of the Program Guidelines is to:

- Guide the delivery of a safe, effective, and high-quality National Lung Cancer Screening Program for the Australian community.
- Standardise the delivery of the program across Australia's health systems, and across multiple service providers.
- Reflect best practice and present a program that is firmly grounded in evidence.
- Provide good practice statements to facilitate equitable program access and delivery for people at high risk of lung cancer in the Australian community.
- Provide a foundation for monitoring and evaluation activities of the program to inform program improvements.

Scope and application

The Program Guidelines include:

- Steps of the screening and assessment pathway, including participant recruitment and eligibility.
- Information about providing smoking cessation advice and support.
- The requirements for shared decision-making.
- Information about the low-dose computed tomography (low-dose CT) request, scan, and assessment.
- Evidence-based recommendations and practice points to provide guidance on appropriate practice (refer to text box on the next page).
- Links to other information and materials supporting the program.



RECOMMENDATIONS ARE DEFINED as those items supported by the Medical Services Advisory Committee (MSAC) expert advice on lung cancer screening and additional items supported by strong evidence (i.e. systematic reviews, randomised controlled trials) (9).



PRACTICE POINTS ARE DEFINED as those points that support and guide program delivery and implementation across the screening and assessment pathway. Practice points are used to address important aspects of program delivery and implementation that are not addressed by other standards or guidelines, or where limited evidence is available.

Practice points were developed based on a number of considerations and inputs including current and emerging evidence (e.g. cohort and case-control studies), current clinical best practice, expert opinion and consensus, stakeholder feedback and insights, and the program's guiding principles (9).

Practice points identify opportunities for the program to intersect with relevant standards/guidelines, and address cross-cutting issues, including:

- access (e.g. health literacy, cost, transport, geography, other support services)
- equity and the barriers and enablers for priority populations
- cultural safety
- the stigma associated with lung cancer and tobacco use
- opportunities to embed smoking cessation across the lung cancer screening and assessment pathway

DRAFT

Overview of the program

The National Lung Cancer Screening Program is a targeted screening program using low-dose CT scans to look for lung cancer in high-risk people without any signs or symptoms suggestive of lung cancer. Screening is recommended every two years, unless a screen detected abnormality is found, and is targeted to people between 50 and 70 years of age with a history of cigarette tobacco smoking.

The program provides free low-dose CT scans to participants. The scope of the program does not include the clinical investigation of screen-detected abnormalities or the diagnosis of lung cancer or other conditions. Therefore, those with a finding suggestive of a lung cancer or an additional finding requiring management should be referred to usual care where best-practice and relevant clinical guidelines and pathways should be followed.

A person's eligibility may be opportunistically assessed for the program when visiting a healthcare provider, likely a general practitioner (GP), for another purpose. They may be proactively identified through their medical records, smoking cessation programs, or other interactions with the health care system and encouraged to visit their GP, or they may self-identify and visit a GP based on information provided about the program.

Those eligible for the program will be referred by an authorised medical practitioner (a GP or specialist) to a radiology provider for a free low-dose CT scan. There are two MBS item numbers specific to the program for radiology providers; one for the 2-yearly low-dose CT scan, and one for the follow-up low-dose CT scans. Both MBS items require mandatory bulk billing of low-dose CT scans.

Low-dose CT scans will be undertaken at fixed radiology services. Mobile screening services will be available in some rural and remote locations to support areas with limited access to radiology infrastructure. The low-dose CT scan will be reported using the National Lung Cancer Screening Program Nodule Management Protocol which is derived from the Pan-Canadian Early Detection of Lung Cancer Study (PanCan) risk calculator (11) for reporting baseline scans and the Lung Imaging Reporting and Data System (Lung-RADS) (12) for reporting follow-up scans. The protocol determines the next steps for the participant in a consistent way: continuation in the program with a low-dose CT scan in 2 years, a shorter interval follow-up scan (in 3, 6 or 12 months) to monitor for nodule growth or changes, or a referral for further investigations. The timely and consistent assessment of low-dose CT scans and reporting results is critical to delivering a safe and effective lung cancer screening program.

The low-dose CT scan results will be sent from the radiology provider to the National Cancer Screening Register (NCSR) as well as being provided to requesting medical practitioners and electronic medical records as per usual practice. Following the low-dose CT scan, the participant will receive communication from the NCSR detailing next steps including if they need to make an appointment with their referring medical practitioner to discuss the results.

Program outcomes

Program aim

The National Lung Cancer Screening Program aims to achieve better health outcomes for Australians by detecting lung cancer early and reducing deaths from lung cancer. Early detection can lead to more effective treatment options and improved outcomes for participants.

Program principles

The program is underpinned by the following eight principles (13):

1. **Accessible:** Access to the program for all eligible participants, inclusive of demographic, geographic, socioeconomic, cultural and other factors.
2. **Agile:** Centred around ongoing application of continuous quality improvement and the implementation of new technologies to ensure the program adapts to change.
3. **Value-based:** Underpinned by efficient investment and high-quality care to create benefits for participants in the form of effective, person-centred cancer screening and improved participant engagement.
4. **Person-centred:** Centred around each individual and delivering benefit to the participant throughout their experience.
5. **Culturally safe for Aboriginal and Torres Strait Islander peoples:** Optimal and culturally safe care for Aboriginal and Torres Strait Islander peoples participating in the program.
6. **Informed by Best Practice:** Informed by evidence and guided by best practice methods, processes and techniques to ensure the program is fit for purpose.
7. **Evidence-based:** Outcomes from research, combined with clinical expertise integrated to underpin scientifically valid recommendations.
8. **Research & Data Driven:** Data used to monitor, evaluate and inform performance and shape the program.

Screening and assessment pathway

The screening and assessment pathway defines the structure of the program.

The program is built around a screening and assessment pathway (the pathway) that is evidence-based and appropriate for the unique Australian context (14). This approach aligns with existing national cancer screening programs for breast, cervical and bowel cancer that include tailored screening and assessment pathways to define clinical and policy parameters and map the participant journey. The pathway supports the delivery of culturally safe, evidence-based and consistent care, and maximises opportunities for primary prevention, especially smoking cessation. Figure 1 presents an overview of the pathway.

Overview of the National Lung Cancer Screening Program Pathway




Figure 1: National Lung Cancer Screening Program Pathway

Target population and eligibility criteria

The program delivers targeted screening to high-risk individuals on a two-yearly basis. Eligibility to participate in the program is assessed using risk-based eligibility criteria recommended by MSAC (15). People are eligible to participate if they:

1. Are between 50 and 70 years of age; and
2. Are asymptomatic (show no signs or symptoms of lung cancer); and
3. Currently smoke or have quit smoking in the past 10 years; and
4. Have a history of cigarette tobacco smoking of at least 30 pack-years.

The eligibility criteria target people known to be at highest risk of lung cancer to help ensure the program is safe and effective. Learn more about [how the eligibility criteria were determined](#) (16).

Low-dose CT scan

There are two new mandatory bulk billing MBS items for low-dose CT scans under the program. The MBS items mean that participants will not have any out-of-pocket costs for the low-dose CT scan through the program.

Heart of Australia will deliver mobile screening services to some rural and remote communities across Australia. Heart of Australia will work with communities before mobile screening days so as many eligible people as possible can get screened while the service is there.

For more information on mobile screening including service delivery routes please visit the Heart of Australia website.

National Cancer Screening Register

The [National Cancer Screening Register](#) (NCSR) provides a single electronic record for each person in Australia participating in the Australian Government's [National Lung Cancer Screening Program](#), [National Bowel Cancer Screening Program](#) and [National Cervical Screening Program](#)

The NCSR supports the program by providing a safety net to participants and healthcare providers to support usual care. The NCSR will support healthcare providers to manage the participant's personal information and participation in the NCSR for lung cancer screening.

The NCSR does not replace usual care including arrangements that healthcare providers may have in place to ensure individuals receive appropriate and optimal care.

The NCSR has developed an interface which allows healthcare providers to integrate their clinical software, supporting seamless access and reporting of clinical data for the program from the patient management software used on a daily basis ([Clinical software integration | National Cancer Screening Register \(ncsr.gov.au\)](#)). Primary care providers and radiologists will have a role in reporting to the NCSR.

Healthcare providers can also use the [NCSR Healthcare Provider Portal](#) which provides a self-service alternative for health professionals to access and submit screening data.

Register your practice

Healthcare providers should register their service or practice to enable NCSR functionality. Practice registration can only be completed if the practice and/or healthcare provider uses one of the integrated partner's software. Further information on clinical software integration, including guides and resources, is available from the [NCSR website](#).

If a practice is already registered with NCSR for bowel or cervical, the practice will not be required to register again.

The NCSR will provide program information and reminders to participants. It will store structured radiology reports of the low-dose CT scans but will not store the scan images. Previous images will need to be accessed as per current practice. Relevant healthcare providers may access participant information and remind them if they need to take action in relation to lung cancer screening. Structured radiology reports will be sent to the NCSR and will also be provided to healthcare providers through usual arrangements. The NCSR does not replace usual care; it assists with reminders and follow-up along the screening pathway.

DRAFT

Navigating the program

The following sections of the Program Guidelines map out each stage of the program and provide guidance, recommendations and practice points for health professionals involved in delivering the program.

Program considerations

Achieving equity in the National Lung Cancer Screening Program

In Australia, there are significant differences in lung cancer outcomes among different population groups. Disparities are strongly associated with various health determinants, such as cultural, social, commercial, environmental, economic, and structural factors. Indigeneity, race, ethnicity, sex, gender, sexuality, where people live, their socioeconomic group, whether they have a disability and the intersections of these factors can contribute to discrimination and/or exposures to cancer risk factors, differences in access to care, lung cancer diagnosis, experiences, and survival rates. These differences highlight the need for targeted, culturally safe approaches to help ensure fair and equitable lung cancer screening and health outcomes for *all* Australians.

Certain populations (listed below) have been identified as priority populations of the program due to an increased risk of lung cancer. This risk can be related to smoking prevalence and systemic health care access barriers (1,8,17,18). These populations often experience limited access to appropriate and safe health services and have a distrust of health care services (18,19) resulting in poorer health outcomes overall. Therefore, ensuring the program and these supporting guidelines meets the needs of identified priority populations will achieve equity and benefit all eligible Australians.

The following groups have been identified as priority populations for the program. We acknowledge that some people may identify with one or more of the following groups:

- Aboriginal and/or Torres Strait Islander peoples
- People living in rural and remote areas
- People from culturally and linguistically diverse (CALD) backgrounds
- People living with disability
- People from the Lesbian, Gay, Bisexual, Transgender, Intersex, Queer and Asexual (LGBTIQA+) communities.

It is important to remember that many different influences can make up a person's identity and their experiences. This can include cultural identity, race, religion, gender identity, sexual orientation or sexuality, where a person lives, age, ability or disability, migration status as well as consideration for the context they are experiencing (20).

The program strives towards equitable and safe delivery for all priority populations. It is critical that healthcare providers across all settings are aware of the program and encourage potentially eligible

people from these priority populations to participate in screening. People within these populations often experience intersectional and compounding barriers to screening and accessing health care (21). It is important to recognise and care for participants in a culturally safe way by being responsive to their values, needs and preferences.

Aboriginal and Torres Strait Islander peoples

These Guidelines recognise the prevailing strength and endurance of Aboriginal and Torres Strait Islander peoples, their families, and communities as the world's oldest living cultures. Aboriginal and Torres Strait Islander peoples are a priority population in the program due to inequities in smoking prevalence and access to optimal and culturally safe and appropriate healthcare, which significantly impacts lung cancer diagnosis, mortality, and survival rates (17,22–26). Despite a significant downward trend, approximately 40% of Aboriginal and Torres Strait Islander peoples smoke (1,27), meaning they are likely to make up a disproportionately large segment of the eligible screening population. In addition, the lung cancer survival rate for Aboriginal and Torres Strait Islander peoples is 11% at five years post diagnosis (24). Such impacts and loss to communities may affect participation rates and the participation experience.

To date, Aboriginal and Torres Strait Islander peoples have low participation across the bowel, breast and cervical screening programs and high rates of positive results requiring follow up (17,22–25). Significant efforts must be made to address the systemic barriers in the Australian health care system which contribute to underscreening and ensure that eligible Aboriginal and Torres Strait Islander peoples are given equitable opportunities to screen for lung cancer (28). Getting the program right for Aboriginal and Torres Strait Islander peoples will ensure it works for all Australians and equity is achieved.

Cultural safety in the National Lung Cancer Screening Program

The program has been co-designed with Aboriginal and Torres Strait Islander peoples and the National Aboriginal Community Controlled Health Organisation (NACCHO) to help ensure it is culturally safe. The Government is committed to working in partnership with Aboriginal and Torres Strait Islander peoples, communities and organisations, recognising that the only way to close the gap is when Aboriginal and Torres Strait Islander peoples' leadership and right to self-determination are upheld so that they may own, commit to and drive the outcomes sought, alongside all governments. The National Agreement on Closing the Gap (National Agreement), the Australian Cancer Plan, and the NACCHO Aboriginal and Torres Strait Islander Cancer Plan are key policies that demonstrate this commitment (29–31).

In realising the commitment made by all Australian Governments and Aboriginal and Torres Strait Islander representatives in the National Agreement, there is an obligation to ensure the program is delivered in a culturally safe way (29). The four Priority Reforms outlined in the National Agreement provide a roadmap to strong and positive ways of working together to create a culturally safe program:

1. Formal partnerships and shared decision-making.
2. Building the community-controlled sector.
3. Transforming government organisations.
4. Shared access to data and information at a regional level (29).

A holistic approach to health and wellbeing requires understanding and addressing cultural determinants. Cultural determinants of health and wellbeing such as family kinship and community, self-determination, Indigenous beliefs and knowledges, connection to Country, Indigenous languages, and cultural expression and continuity, are all strongly identified as having a positive impact on the health and wellbeing outcomes of Aboriginal and Torres Strait Islander peoples. Connection is a key component of Aboriginal and Torres Strait Islander cultures. It recognises the importance of kinship and connection to Country physically, spiritually, and through traditional knowledge sharing and storytelling.

The Australian Cancer Plan and the Aboriginal and Torres Strait Islander Cancer Plan highlight the importance of mainstream health services working collaboratively and in reciprocity with Aboriginal Community Controlled Health Organisations (30,31).

All healthcare providers have a responsibility to deliver culturally safe healthcare services. Australian Health Practitioner Regulation Agency (Ahpra) defines cultural safety as being determined by Aboriginal and Torres Strait Islander individuals, families and communities. Culturally safe practice is the ongoing critical reflection of health practitioner knowledge, skills, attitudes, practising behaviours and power differentials in delivering safe, accessible and responsive healthcare free of racism (32). As outlined by Ahpra, to ensure culturally safe and respectful practice, health practitioners must:

- Acknowledge colonisation and systemic racism, and social, cultural, commercial and economic factors which impact individual and community health and wellbeing.
- Acknowledge and address individual racism, their own biases, assumptions, stereotypes and prejudices and provide care that is holistic, free of bias, racism and discrimination.
- Recognise the importance of self-determined decision-making, partnership and collaboration in health care which is driven by the individual, family and community.
- Foster a safe working environment through leadership to support the rights and dignity of Aboriginal and Torres Strait Islander peoples and colleagues (32).

More information of Ahpra's Aboriginal and Torres Strait Islander Health Strategy is available [here](#).

Collaboration is critically important as it is through Aboriginal and Torres Strait Islander leadership, including leadership from Aboriginal and Torres Strait Islander Health Workers and Health Practitioners, that equitable, culturally safe and responsive health care can be delivered for Aboriginal and Torres Strait Islander peoples and communities (30). This collaboration is critically important to the success of the program, as people are supported through the entire screening and assessment pathway to achieve the best possible outcomes (31).

Addressing smoking stigma

Lung cancer screening differs from other cancer screening programs as program eligibility is driven by exposure to a risk factor – tobacco use – and specifically smoking cigarettes, which is highly stigmatised (33,34). Lung cancer, as a disease explicitly linked to tobacco use, is consequently highly stigmatised for individuals diagnosed with the disease, their families and carers. Many Australians express victim-blaming

mentalities towards people diagnosed with lung cancer (35). Experiences of stigma associated with lung cancer are also often perpetuated within health care settings (36).

Stigma attached to smoking, nicotine dependence, and lung cancer can undermine health care access through internalised perceptions that the disease is self-induced (37,38). Stigma can manifest as guilt, shame, anxiety, and depression (35,39) and is strongly related to delays or avoidance in seeking supports from GPs and others when needed (40). Stigma can also negatively impact the delivery of care and a person's psychosocial and quality of life (QOL) outcomes (41).

Stigma, along with other factors, can negatively impact how people who smoke or who have a history of smoking engage with lung cancer screening (37,41,42). Stigma represents a significant deterrent and can create unsafe care environments. This may lead to non-participation in lung cancer screening and delay people from seeking treatment and supports. Stigma can also hinder acceptance of smoking cessation supports (43) and open communication about cancer, including among families and communities (44), which may further exacerbate the potential for unsafe care, delays or non-participation in lung cancer screening.

To counter stigma in health care, health professionals should acknowledge the role of the tobacco industry as well as structural and historical determinants of health-related behaviours, care, and outcomes (44). Minimising stigma and shame associated with tobacco use and cancer risk is critical, while recognising that the tobacco industry actively promotes and sells highly addictive products across Australia (45). Stigma can be addressed in the program through collaborative efforts towards changing beliefs, attitudes and behaviours, while avoiding blame-focused discourse. Addressing participants' psychosocial needs (see below) and promoting and utilising shared-decision making are key strategies for reducing stigma. This can assist to maximise the uptake of lung cancer screening (44,46). Everyone deserves care, support, and understanding (35).

Psychosocial care

Stigma, coupled with scan anxiety and fear of diagnosis stemming from screening for lung cancer, means that the psychosocial impact may be profound for some participants and their families. Creating culturally safe space for individuals to discuss their lived experiences and individual needs can help to reduce anxiety and increase safety (47). Healthcare providers should be prepared to offer or refer to psychosocial care; an approach to care which accounts for the whole person, addressing social, psychological, emotional, spiritual, and functional aspects of the participant journey (48,49). This includes ensuring that the participant is aware of professional supports available, such as psychological counselling services, financial and travel assistance, or support groups. Support should be offered whenever it is appropriate and necessary. Information and support should be delivered in a sensitive manner and tailored to individual participant characteristics such as: age, health literacy, cultural identity, religion, mental health concerns, gender, sexuality, and language spoken.



Practice Points

Priority populations: Priority population groups of the program include:

- Aboriginal and Torres Strait Islander peoples
- People living in rural and remote areas
- People from culturally and linguistically diverse backgrounds
- People living with disability
- People from the Lesbian, Gay, Bisexual, Transgender, Intersex, Queer and Asexual (LGBTIQA+) communities.

Ensure priority populations have equitable access to screening and tailor approaches to provide safe and appropriate care. Some individuals may identify with one or more of the above groups.

Cultural safety: It is the responsibility of all healthcare providers and administrative staff to ensure a culturally safe lung cancer screening program. All staff involved in the program should engage in formal cultural safety training.

Data collection: Appropriate collection of participants' data is necessary for an inclusive and safe program. Ensure all data points are collected appropriately, accurately, and completely.

Collect and record Indigenous status: Aboriginal and Torres Strait Islander status should be accurately and consistently collected and recorded on all relevant program forms and clinical records, in accordance with the Australian Bureau of Statistics classification and standards, this will support monitoring and evaluation of equity in the program.

Stigma: Stigma can negatively impact participation in screening. All conversations should be free of judgement, non-stigmatising, empathetic and consider social and emotional wellbeing.

Psychosocial support: Healthcare providers should offer psychosocial support and refer to psychosocial services where appropriate. Individuals should be provided an opportunity to discuss their lived experiences and specific needs.



Resources

[Cancer Council – Patient Support Services](#)

[Lung Foundation Australia – services](#)

How to communicate about lung cancer screening and reduce stigma – *in development*

Providing support for lung cancer screening participants – Psychological impacts and factors associated with lung cancer screening – *in development*

Smoking cessation

The provision of smoking cessation supports are an important component of any effective and equitable lung cancer screening program, with evidence from trials showing that participants have higher quit rates than rates expected in the general population (38). Tobacco use is highly addictive and is the single greatest avoidable risk factor for lung cancer (6). For people who smoke, quitting smoking is the best way to reduce lung cancer risk and improve health outcomes (50). While the program is targeted to people

with a history of tobacco cigarette smoking, smoking cessation is an opportunity to discourage all forms of smoking.

People who smoke do not have to quit smoking to participate in the program.

Healthcare providers can access [clinical tools and guidelines for smoking cessation support](#) via Quit Centre.

How to implement – recommendations and practice points

Smoking cessation supports are to be offered to all potential participants by healthcare providers across the lung cancer screening and assessment pathway.

Smoking cessation support(s) should be [embedded into everyday practice](#) in the delivery of the program. Smoking cessation interventions can be offered according to [current Australian smoking and nicotine cessation clinical guidelines](#) available from the Royal Australian College of General Practitioners (RACGP) (51).

Best practice smoking cessation interventions

It is strongly recommended that the 3-step brief intervention model 'Ask, Advise, Help' (AAH) be utilised across the screening and assessment pathway as it can be delivered in a short time, by any healthcare provider, and in any setting due to the low intensity and minimal resourcing required (36):

1. **ASK** and record if the person smokes;
2. **ADVISE** people who smoke on the most effective quit methods;
3. **HELP** to arrange a referral to multi-session behavioural interventions and pharmacotherapy.

The 'HELP' step can involve a referral directly to tobacco treatment specialists, the Quitline ([via jurisdictional web form](#)), and/or the [My QuitBuddy app](#) as appropriate. Healthcare providers should ensure the individual has provided informed consent for the Quitline referral and agreed to be contacted by Quitline.

How should smoking cessation supports be offered?

Smoking cessation supports should be offered in a way that is understanding of, and empathetic to the person's experience of nicotine dependence. People who smoke experience stigma due to the misconception that smoking is a 'lifestyle choice' or 'personal choice' and often face a victim-blaming mentality towards smoking-related disease. Healthcare providers should acknowledge that tobacco use is driven by harmful commercial interests and entrenched normalisation, particularly as an ongoing impact of colonisation for Aboriginal and Torres Strait Islander peoples and communities (45).

Healthcare providers can help address and minimise stigma by acknowledging that nicotine dependence is a clinical condition that can be treated (35). Non-judgmental and person-centred terminology is encouraged rather than labels (see the [International Association for the Study of Lung Cancer \(IASLC\) language guide](#)). Individuals can be supported by healthcare providers highlighting the benefits of quitting smoking and focusing on the positive impacts, including physical, psychological, financial, and social benefits (52). Each person's interest in and responsiveness to smoking cessation supports will be different. Individuals should not be coerced or pressured and should not be made to feel guilty if they do not quit.

Initiatives to support equity and culturally safe smoking cessation supports

- Cessation medicines, including varenicline and bupropion are subsidised on the PBS, and can be accessed with a prescription
- Free nicotine replacement therapy (NRT) is available in some jurisdictions through Quitline
- Pharmacotherapies may be free for Aboriginal and Torres Strait Islander peoples if they are eligible for the Closing the Gap co-payment. However, it is important to note that oral NRT is not currently available on the PBS and therefore not covered under the Closing the Gap co-payment
- All Quitline services nationally have Aboriginal and/or Torres Strait Islander counsellors and/or advisors to provide a culturally safe quitting service to Aboriginal and Torres Strait Islander peoples. Aboriginal Quitline services are also available in Victoria, Western Australia, South Australia and Northern Territory
- Online and app-based tools can be recommended to participants to support monitoring of smoking cessation progress (e.g. QuitCoach and My QuitBuddy).

Aboriginal and Torres Strait Islander peoples and smoking cessation

The program aligns with the [National Tobacco Strategy](#) and complements Australia's track record in reducing tobacco-related disease and mortality by systematically embedding smoking cessation support within the pathway (38,53). The National Tobacco Strategy identifies greater access to cessation services as a key priority area in reducing smoking prevalence. The National Tobacco Strategy also identifies specific actions towards achieving cultural safety and best practice in providing access to, and the delivery of tobacco/nicotine cessation supports, particularly for Aboriginal and Torres Strait Islander peoples and priority populations (54).

Aboriginal and Torres Strait Islander peoples require tailored approaches and access to culturally safe and appropriate smoking cessation supports and services (25). The majority (70%) of Aboriginal and/or Torres Strait Islander peoples who smoke want to quit (55).

When supporting Aboriginal and Torres Strait Islander individuals to quit smoking within the context of the program, it is important that healthcare providers recognise specific barriers to smoking cessation, and the ongoing colonial history that has systemically entrenched commercial tobacco use in communities (28,56–58).

Barriers to cessation include the normalisation of smoking in communities and as a social activity, and the use of tobacco as a coping mechanism for stress linked to intergenerational trauma (59). Leveraging family and community support for smoking quit attempts has been shown to be effective to address these barriers. Barriers also exist in accessing mainstream smoking cessation services, such as online supports and Quitline, including cultural safety, language and phone accessibility, preference for face-to-face interventions, and access to affordable NRT options (60,61).

Healthcare providers need to consider individual preferences, access, cultural appropriateness, and personal circumstance when supporting smoking cessation (56). Healthcare providers can refer individuals to culturally safe services for Aboriginal and Torres Strait Islander peoples, including Aboriginal Community Controlled Health Organisations and the Quitline which offers support from Aboriginal and Torres Strait Islander counsellors and advisors. The Tackling Indigenous Smoking (TIS) program works at a population health level to support Aboriginal and Torres Strait Islander communities to reduce the prevalence of smoking. A range of culturally appropriate resources and factsheets are available on the [TIS website](#).



Recommendations

All people who currently smoke or have recently quit should be offered support to quit smoking using the 3-step brief intervention model – ASK, ADVISE, HELP

Smoking cessation supports are to be offered to all potential participants by healthcare providers across the screening and assessment pathway. This includes follow-up and maintenance support.

Offer follow-up support to all people who are attempting to quit smoking.

Referral to telephone call-back counselling services can be offered to all people who smoke (where appropriate).



Practice Points

Current smoking: Participants do not have to quit smoking to participate in the program.

Smoking cessation interventions: Healthcare providers should ensure individuals have access to effective and culturally safe best-practice smoking cessation interventions, including pharmacotherapy and behavioural counselling or as recommended in [current Australian smoking and nicotine cessation clinical guidelines](#).

Smoking cessation specialists: Healthcare providers can refer individuals to specialist tobacco via Quitline and/or local smoking cessation support services and online web-based supports. Ensure the individual consents for referral.

Documentation of smoking history: Updated smoking history records enables identification of people eligible for the program and to offer smoking cessation support to people who currently smoke.

Data collection: Healthcare providers should capture information on smoking cessation supports being offered during relevant consultations and the type of smoking cessation support that was offered. This will be captured in the Healthcare provider enrolment and eligibility form and participant management form.

Stigma: Smoking cessation support should be delivered without judgement to avoid stigmatising the person. Individuals should not be coerced or pressured into quitting smoking.

Cultural safety: Smoking cessation support must be culturally safe and appropriate for the individual. Ensure individual needs and preferences are considered and utilise tailored resources.



Resources

[RACGP Smoking Cessation Guidelines](#)

[Quit - National Smoking Cessation Platform](#)

Ph: 13 78 48

[Quitline for Aboriginal and Torres Strait Islander Communities](#)

Ph: 13 78 48

[Quit Centre for Health Professionals](#)

[My QuitBuddy app](#)

[Tackling Indigenous Smoking \(TIS\) program](#)

[IASLC Language Guide](#)

Smoking cessation resources guide – *in development*

Promotion and awareness

Summary - what will happen?

Program promotion and awareness-raising are integral to maximise participation in the program. Promotion that is widespread and frequently repeated will help to reach potentially eligible people and inform the broader Australian community.

Governments, service providers and healthcare professionals have a joint responsibility to proactively promote the program to support recruitment of potential participants.

Lack of awareness and understanding of the benefits of screening are the most significant barriers to participation in international lung cancer screening programs (37,62,63). Tailored promotion of the program in both healthcare and community settings will reduce barriers to screening and increase participation of eligible people, including those from priority populations (64,65). Positive messages from healthcare providers about the benefits of lung cancer screening can facilitate [cultural safety](#) and [address stigma](#). Repeated provision of information improves participation in lung cancer screening programs and reduces barriers (66) such as the time constraints placed on GP consultations and competing demands for limited healthcare resources (62).

How to implement – practice points and recommendations

The program should be promoted in ways that are culturally safe, appropriate and accessible, account for various levels of literacy and health literacy, and address stigma.

Along with national campaigns, healthcare providers play an important role in recommending screening and disseminating information. Healthcare providers can engage in promotion and raising awareness of the program by:

- Familiarising themselves with specific information and education resources about the program including eligibility criteria, what a low-dose CT scan is, benefits and risks of screening, any costs involved, and referral processes for further investigations and follow-up (67).

- Clearly articulating program information to a wide range of audiences in plain language. Communication resources need to cater to people from a broad range of backgrounds. Resources are available in a range of community languages. Professional interpreters should be engaged where appropriate.
 - Community champions may facilitate the promotion of public health programs in their communities (68).
- Recommending lung cancer screening to patients in their practices (69).
- Utilising existing resources to ensure adherence to key messaging of the program (70).
- Promoting the program into existing community health education sessions and existing cancer screening programs for breast, bowel and cervical cancers.
- Repeating key messages about the program to the general public to help disseminate information widely across communities.



Practice Points

Target audiences: Consider the information needs of lung cancer screening priority populations, including Aboriginal and Torres Strait Islander peoples. Use resources and key messages that have been tailored for priority populations where available [link to be added when available]

Engagement and awareness building: When engaging priority populations, including Aboriginal and Torres Strait Islander peoples, involve trusted community members, organisations, and healthcare professionals, such as Aboriginal Health Workers and Practitioners, in promoting the lung cancer screening program and raising awareness within the community

Accessibility: Promotion materials to be in plain language and easy to understand. Program resources to be offered in easily accessible ways.

Offer multiple opportunities to access information: Information about the program should be repeated and available in multiple formats and across multiple timepoints. Repetition increases information absorption and will complement general public awareness (66).

Readiness: Strategies to get health services ready for the program are available from the program website [insert link when ready]. Engaging community healthcare workers is an effective means of educating the general public and reaching people at high risk of lung cancer.



Resources

Department awareness campaign material to promote the NLCSP – *in development*

Healthcare provider roles and responsibilities

A summary of healthcare providers' roles and responsibilities across the screening and assessment pathway is detailed in Table 2. A simplified pathway summarising the program healthcare setting and roles and responsibilities is provided in Figure 2.

Table 1: Roles and responsibilities across the screening and assessment pathway

	Program entry and supporting choice	Low-dose CT scan and reporting	Management of results, follow-up and reminders	
Indicates a task that can be performed by an authorised medical practitioner in the program.				
Authorised Medical Practitioners	General Practitioners	<ul style="list-style-type: none"> Promote the program Identify and invite participants Assess and confirm eligibility Check low-dose CT suitability Facilitate shared decision making Enrol participant with the NCSR Request low-dose CT scan Offer smoking cessation supports 	<ul style="list-style-type: none"> Assist participant to arrange appointment Help to identify and arrange supports needed for low-dose CT scan 	<ul style="list-style-type: none"> Communicate results to participant Refer to a respiratory physician linked to a lung cancer multidisciplinary team for ongoing management Manage additional findings according to existing clinical guidelines Provide and organise social, emotional wellbeing support and maintain holistic perspective of lung and general health Access participant low-dose CT screening histories from NCSR Ensure reminders are enabled in participant record in practice software Offer smoking cessation supports
	Medical Specialists and other Medical Practitioners	<ul style="list-style-type: none"> Promote the program Identify and invite participants Assess and confirm eligibility Check low-dose CT suitability Facilitate shared decision making Enrol participant with the NCSR Request low-dose CT scan Offer smoking cessation supports 	<ul style="list-style-type: none"> Assist participant to arrange appointment 	<ul style="list-style-type: none"> Communicate results to participant Refer to respiratory physician linked to a lung cancer multidisciplinary team for ongoing management Manage additional findings according to existing clinical guidelines Provide and organise social, emotional wellbeing supports

		Program entry and supporting choice	Low-dose CT scan and reporting	Management of results, follow-up and reminders
Indicates a task that can be performed by an authorised medical practitioner in the program.				
				<ul style="list-style-type: none"> • Access participant low-dose CT screening histories from NCSR • Ensure reminders are enabled in participant record in practice software • Offer smoking cessation supports
	Radiologists (specific to the program)		<ul style="list-style-type: none"> • Read and assess low-dose CT scan • Complete structured radiology report 	<ul style="list-style-type: none"> • Access program participant low-dose CT screening histories from NCSR • Send report to the NCSR • Send report to requesting authorised medical practitioner
Healthcare providers without authorisation to request a low-dose CT scan	Radiographers		<ul style="list-style-type: none"> • Perform low-dose CT scan 	
	Practice Nurses, Nurse Practitioners, Registered Nurses and Enrolled Nurses	<ul style="list-style-type: none"> • Promote the program • Identify and invite participants • Assess eligibility • Facilitate shared decision making • Enrol participant with the NCSR • Offer smoking cessation supports • Facilitate recall and reminders 	<ul style="list-style-type: none"> • Assist participant to make appointment (advice on participating radiology providers) 	<ul style="list-style-type: none"> • Support results communication • Ensure reminders are enabled in participant record in practice software • Support care coordination • Offer smoking cessation supports
	Aboriginal and Torres Strait Islander Health Workers and Practitioners	<ul style="list-style-type: none"> • Promote the program • Identify and invite participants • Assess eligibility • Facilitate shared decision making • Enrol participant with the NCSR • Offer smoking cessation supports • Facilitate recall and reminders 	<ul style="list-style-type: none"> • Assist participant to make appointment (advice on participating radiology providers) • Help to identify and arrange supports needed for low-dose CT scan 	<ul style="list-style-type: none"> • Support results communication • Ensure reminders are enabled in participant record in practice software • Support care coordination • Offer smoking cessation supports
	Allied Health Professionals	<ul style="list-style-type: none"> • Promote the program • Recommend an eligibility assessment • Offer smoking cessation supports 		<ul style="list-style-type: none"> • Offer smoking cessation supports

		Program entry and supporting choice	Low-dose CT scan and reporting	Management of results, follow-up and reminders	
Indicates a task that can be performed by an authorised medical practitioner in the program.					
Administrative staff (based in primary care)	Practice Managers and Administrative staff	<ul style="list-style-type: none"> Promote the program Identify and invite participants Facilitate recall and reminders 	<ul style="list-style-type: none"> Assist participant to make appointment (advice on participating radiology providers) 	<ul style="list-style-type: none"> Ensure reminders are enabled in participant record in practice software Ensure NCSR is integrated with practice software 	
	Health support workers (in health promotion, disability support, mental health, bicultural workers etc)	Aboriginal Liaison Officers	<ul style="list-style-type: none"> Promote the program Recommend an eligibility assessment 	<ul style="list-style-type: none"> Assist participant to make appointment Help to identify supports needed for low-dose CT scan 	<ul style="list-style-type: none"> Support results communication Offer smoking cessation support within their scope of practice
	Health support workers (in health promotion, disability support, mental health, bicultural workers etc)	Health Support Workers	<ul style="list-style-type: none"> Promote the program Recommend an eligibility assessment 	<ul style="list-style-type: none"> Assist participant to make appointment Help to identify supports needed for low-dose CT scan 	<ul style="list-style-type: none"> Support results communication Support care coordination
Health support workers (in health promotion, disability support, mental health, bicultural workers etc)	Smoking Cessation Specialists	<ul style="list-style-type: none"> Promote the program Recommend an eligibility assessment Offer smoking cessation supports 	<ul style="list-style-type: none"> Offer smoking cessation supports 	<ul style="list-style-type: none"> Offer smoking cessation supports 	




Figure 2: Simplified pathway summarising the program healthcare setting and roles and responsibilities

Program entry and recruitment

Summary – what will happen?

Recruitment involves identifying and engaging potentially eligible individuals who are at high risk of developing lung cancer to participate in the program.

As the program is a targeted screening program with risk-based eligibility criteria, participants cannot be identified solely based on age through means such as Medicare or the electoral roll. For this reason, the NCSR does not issue invitation letters as it does for bowel and cervical cancer screening programs.

There are four routes for potential participants to enter the program:

- **ORGANISED ENTRY** A potential participant is proactively identified by a primary care practice through existing patient records (e.g. electronic medical records (EMR) or practice databases) based on their age and smoking history. Other risk factors, for example, respiratory conditions, provide an opportunity to identify people through an organised entry pathway. Individuals are proactively invited to participate in an eligibility assessment which is confirmed by an authorised medical practitioner who also provides the low-dose CT request.
- **OPPORTUNISTIC ENTRY** A potential participant is identified by a healthcare provider during an unrelated consultation. The healthcare provider offers to complete an eligibility assessment for the potential participant either during the same consultation or at another time. If the consulting healthcare provider is authorised to order a low-dose CT request, they may do so directly following confirmation of eligibility. EMR-based approaches could be established to flag potentially eligible participants and prompt the healthcare provider to opportunistically ask about lung cancer screening.
- **FACILITATED ENTRY** plays an important role in reaching potential participants who may not have a regular primary care provider and provides an alternative access point that may be more appropriate for some priority populations. Facilitated entry may include supporting the potential participant to arrange a primary care appointment and/or engaging a support person such as a family member or community worker to support them. Healthcare providers or health support workers can identify individuals who are potentially eligible for the program (for example a Quitline counsellor may encourage a potential participant to see their GP for an eligibility assessment). Liaison with an authorised medical practitioner is then required to confirm eligibility and complete a low-dose CT request.
- **SELF-IDENTIFIED ENTRY** A potential participant proactively seeks an eligibility assessment from an authorised medical practitioner who can confirm eligibility and complete a low-dose CT request.

The four entry routes into the program allow for flexible ways to identify potential participants. All routes lead to an eligible participant receiving a low-dose CT scan request from an authorised medical practitioner.

Recruitment Settings

Recruitment into the program occurs across multiple settings, including primary health care practices, Aboriginal Community Controlled Health Organisations/Medical Services, allied health settings, community primary care services and hospital-based services.



Practice Points

Organised entry: Primary care practices can use existing clinical software-integrated mechanisms to conduct EMR audits to identify potential participants who meet the eligibility criteria and proactively send an invitation to consider screening via usual practice communication methods (e.g. letter, SMS).

Opportunistic entry: Practices can establish Electronic Medical Record (EMR)-based prompts to flag potentially eligible participants during consultations to enable opportunistic identification of potential participants.

Eligibility self-assessment: Individuals may have self-assessed their own eligibility prior to consulting a healthcare provider. An authorised medical practitioner needs to confirm and record screening eligibility before a low-dose CT scan can be requested.

Smoking status and history: Healthcare providers should regularly update and review the accurate recording of smoking status and history into EMRs to efficiently identify potential participants. Data collection should include:

- Cigarette tobacco smoking history (current/former/never)
- Start smoking age (years)
- Quit smoking age (years) if applicable
- Duration smoking (years)
- Average daily cigarette consumption (number of cigarettes)

Smoking cessation: Updated smoking history records enables smoking cessation supports to be offered to people who currently smoke. Smoking cessation supports should be offered to all individuals who currently smoke or who have recently quit.

Access: Healthcare providers to offer tailored support options and/or services where appropriate. Consider potential participant's access to an authorised medical practitioner and screening site, including transportation and appointment booking.



Resources

For general audience – *in development*:

- What is the National Lung Cancer Screening Program
- About lung cancer
- Patient pathway infographic
- Frequently asked questions

For healthcare providers – *in development*:

- Key evidence for the Program
- Flowchart for eligibility and low-dose CT request
- GP resource guide
- Frequently asked questions
- Communicating lung cancer and reducing stigma
- Conversation starters

Eligibility and low-dose CT scan request

Summary – what will happen?

A wide range of [healthcare providers](#) may discuss and check if people are eligible to participate in the program, such as nurses and Aboriginal and Torres Strait Islander Health Workers or Practitioners. Eligibility to participate in the program should be confirmed by an [authorised medical practitioner who will complete a low-dose CT request](#). Individuals need to meet all four eligibility criteria listed below to participate in the program.

There are no program-specific MBS items for the eligibility assessment. Existing MBS items for general practice consultations should be used.



DRAFTING NOTE: The Department of Health and Aged Care is developing several forms for the program such as the Healthcare Provider Eligibility and Enrolment form and the Diagnosis form. These forms will be available through the NCSR

Eligible participants are not required to stop smoking to participate in the program.

Once an individual is participating in the program, there is no requirement to reassess eligibility. A participant remains eligible for lung cancer screening within the program until they [exit the program](#). The participant remains eligible to continue in the program until they age out, become unable to undergo a scan or have findings on scans that mean they exit the program.

A medical practitioner should also check the [low-dose CT scan suitability](#) of all people eligible to participate in the program prior to completing a [low-dose CT scan request](#).

National Lung Cancer Screening Program eligibility criteria:

1. Are aged between 50 and 70 years; and
2. Are asymptomatic (no signs or symptoms suggestive of lung cancer); and
3. Currently smoke or have quit smoking in the past 10 years; and
4. Have a history of cigarette tobacco smoking of at least 30 pack-years (15).

How to implement – recommendations and practice points

How to calculate smoking pack-year history

To determine eligibility a healthcare provider needs to calculate a person's pack-year history, this relies on a person's recall of their smoking history. This means that calculating pack-years is an 'imperfect science' and healthcare providers will need to use clinical judgement and best estimates to determine if a person is eligible to participate in the program. Healthcare providers should encourage individuals to provide their best estimate of their smoking history/habits and acknowledge that this estimate may vary

depending on a range of factors (e.g. use of tobacco pouch, sharing packets of cigarettes). Pack-year history will not be recorded in the NCSR.

Authorised medical practitioners are advised to use **clinical judgement and best estimates** to confirm if a person is eligible to participate in the program when calculating pack-year smoking history.

Pack-years is a way of measuring the number of cigarettes a person has smoked in their lifetime.

Pack-years are calculated by **multiplying** the **number of packs of cigarettes smoked per day** by the **number of years the person has smoked**. For example, 1 pack year is equal to smoking 1 pack per day for 1 year. For the purposes of this calculation a pack is equal to 20 cigarettes.

Healthcare providers should ask a person:

- How many years have you smoked tobacco cigarettes?
- On average, how many tobacco cigarettes have you smoked per day?

Calculate pack-years

x =

NUMBER OF YEARS SMOKED AVERAGE NUMBER OF PACKS SMOKED PER DAY (one pack equals 20 cigarettes) PACK-YEARS

A case study example of how to calculate smoking history:

- A 55-year-old person sees their GP to assess their eligibility to participate in the program. They quit smoking 6 years ago. Prior to that they would on average smoke 2 packets of 20 cigarettes per day for 15 years.
- This equates to 30 'pack-years'. This smoking history makes the person eligible for the program and they agree to commence screening.

After being in the program for 5 years, the participant has continued to not smoke, and it had now been 11 years since they quit.

Telehealth

Assessment of eligibility by an authorised medical practitioner could occur via a telehealth appointment. [Telehealth MBS items](#) can be used if:

- The authorised medical practitioner and individual have an existing clinical relationship.
- The individual has visited the practice for a face-to-face service in the last 12 months.

Please note, there are [some exemptions to this rule](#). These exemptions are important to consider for opportunistic entry into the program. Some relevant exemptions could include for (71):

- People experiencing homelessness.

- People needing mental health support.
- People receiving treatment in an Aboriginal Medical Service (AMS) or an Aboriginal Community Controlled Health Organisation (ACCHO).

Managing symptomatic participants

If an individual is found to have signs and symptoms suggestive of lung cancer at any point of the screening and assessment pathway, an authorised medical practitioner should investigate these according to Cancer Australia's guide for [Investigating Symptoms of Lung Cancer: a guide for all health professionals](#)(72) and manage the patient according to the [Optimal Care Pathway for people with lung cancer or the Optimal Care Pathway for Aboriginal and Torres Strait Islander People with Cancer](#) (73,74). [It is vital that this happens in a timely way to ensure the prompt investigation of any possible indications of lung cancer.](#)



Recommendations

Eligibility assessment: Assess if an individual meets the program eligibility criteria to participate in the NLSCP:

1. Are aged between 50 and 70 years of age and
2. Are asymptomatic (no signs or symptoms suggestive of lung cancer); and
3. Currently smoke or have quit smoking in the past 10 years; and
4. Have a history of cigarette tobacco smoking of at least 30 pack-years (15).



Practice Points

Pack-years: Calculating pack-years is an 'imperfect science' and healthcare providers should use clinical judgement and best estimates to calculate smoking pack-years when determining program eligibility.

Confirming eligibility: Participants must satisfy all screening eligibility criteria. Confirm eligibility and check for low-dose CT scan suitability prior to providing a low-dose CT request.

Data collection: Record patient information on the Healthcare Provider Eligibility and Enrolment form, including preferences for their data to be on the NCSR, their suitability for a Low-Dose CT scan, their Indigenous status, smoking cessation support and advice, family history of lung cancer, prior diagnosis of Emphysema. This data will inform program monitoring and quality. These data will inform program monitoring and quality.

Reassessment: Individuals assessed as not currently eligible for the program but who may meet the criteria as they age or accumulate additional pack years of smoking should be reassessed as soon as they meet the eligibility requirements.

Psychosocial support: Healthcare providers to offer tailored psychosocial support options and/or services where appropriate. People may experience distress or fear about being at high risk of lung cancer or have concerns or feel anxious about not being screened.

Smoking cessation: Smoking cessation support should be offered to all individuals who currently smoke or who have recently quit regardless of actual participation in screening.



Resources

For general audience – *in development*:

- Visiting the radiology clinic (or mobile screening service)
- Patient pathway infographic
- Frequently asked questions

For healthcare providers – *in development*:

- Key evidence for the Program
- Flowchart for eligibility and low-dose CT request
- GP resource guide
- Frequently asked questions
- Communicating lung cancer and reducing stigma
- Conversation starters
- Smoking cessation resources guide
- Screening and assessment pathway infographic with roles and responsibilities at each stage

Suitability for low-dose CT

The lung cancer screening program uses low-dose CT scans of the chest to screen people for lung cancer. An [authorised medical practitioner](#) will need to check low-dose CT suitability of all people eligible to participate in the program prior to completing each low-dose CT scan request.

Summary – what will happen?

An authorised medical practitioner will assess whether individuals are suitable for low-dose CT to ensure the scan is clinically appropriate.

Suitability for low-dose CT needs to be checked by an authorised medical practitioner prior to each low-dose CT scan request, including the baseline scan and all follow-up scans. This involves checking whether people are suitable to have a low-dose CT scan based on their general health alongside factors relating to a person's ability to physically access and use CT scanners.

Most people will be able to undergo a low-dose CT scan, however some people will be eligible to participate in the program but may be unsuitable for a low-dose CT and unable to complete a scan. A person's suitability may be temporary and change over time.

How to implement – practice points and recommendations

Authorised medical practitioners should check suitability for low-dose CT:

- For all people eligible to participate prior to completing a low-dose CT scan request
- Prior to each low-dose CT scan request, including the baseline scan and all follow-up scans.

Suitability for low-dose CT is based on specific criteria such as being able to lie flat for a minimum of 5 minutes to complete a low-dose CT scan.

Low-dose CT suitability

People may be considered unsuitable for low-dose CT if:

- Weight exceeds restrictions of scanner (>200kg depending on the scanner)
- Unable to lie flat for a minimum of 5 minutes.
- Symptomatic lung infection (e.g. COVID-19, pneumonia, bronchitis, lower respiratory tract infection with productive cough) within the previous 12 weeks
- Full CT scan of the chest within last 12 months or planned for clinical reasons (e.g. active cancer surveillance) in next 3 months.

It is preferable for people to lift their arms above their head for a low-dose CT scan. For people unable to hold their hands above their head for a low-dose CT scan, the scan can usually still be performed with hands by their side and a very small increase in radiation dose.

Medical practitioners should consider if participants have any other health reasons that may mean a low-dose CT scan is clinically inappropriate and these people should be managed as per usual care arrangements. Significant co-morbidities that preclude investigation and treatment of lung cancer, such as severe chronic obstructive pulmonary disease (75) or poor functioning status (such as Eastern Cooperative Oncology Group (ECOG) 3-4 on the ECOG Performance Status Scale) (76) should be considered during a [shared decision-making](#) discussion, as they may make people unsuitable for screening. However, suitability for lung cancer surgery should not be a contraindication for screening, as patients with comorbidities such as significant COPD or cardiovascular disease can safely be treated with stereotactic ablative body radiotherapy (SABR) with minimal toxicities (77).



Practice Points


Suitability for low-dose CT: Authorised medical practitioners check suitability for a low-dose CT scan for all people eligible to participate in the program. Complete this check prior to completing a low-dose CT scan request at baseline and all subsequent scans.

Documentation: Record suitability for a low-dose CT scan on the Healthcare Provider Eligibility and Enrolment form and the Participation Management form (at all subsequent appointments to provide a new low-dose CT scan request) (Yes/No). Note: if not suitable due to temporary reasons, the healthcare provider should record the date for when they are suitable in the form.

For individuals assessed as suitable for low-dose CT and able to undergo a low-dose CT scan, authorised medical practitioners and/or healthcare providers should engage in a shared decision-making discussion to allow potential participants to make an informed choice about screening.

For those assessed as unsuitable for screening low-dose CT and unable to undergo a low-dose CT scan, practice points specific to each low-dose CT unsuitability criteria are provided in Table 3.

Table 2: Low-dose CT unsuitability criteria and associated practice points

Low-dose CT unsuitability criteria	Rationale	 Practice point
<p>Weight exceeds restrictions of scanner (>200kg depending on the scanner).</p>	<p>Morbid obesity is a potential issue that may result in participants being temporarily unable to be scanned due to exceeding the weight restrictions of the scanner.</p>	<p>If an individual weighs >200kg, health professionals and/or program participants to check suitability with radiology provider.</p> <p>Note: many radiology service providers routinely ask people to confirm their weight at the time of booking a low-dose CT scan to clarify that it does not exceed the weight restrictions of the scanner.</p> <p>Actively recall participants unsuitable for low-dose CT scan due to exceeding weight restrictions of the scanner at two-year intervals to reassess low-dose CT suitability. This can be done via the NCSR pause participation function. Practice-based recalls can be used for people who opt-out of the NCSR.</p>
<p>Unable to lie flat for a minimum of 5 minutes.</p>	<p>A low-dose CT scan requires participants to lie on their back, on a flatbed that passes into the CT scanner. Patients need to hold their breath for a few seconds and stay still while each scan is taken so that the images are clear.</p>	
<p>Symptomatic lung infection (e.g. COVID-19, pneumonia, bronchitis, lower respiratory tract infection with productive cough) within the previous 12 weeks.</p>	<p>Lung infections may result in limited visibility of the lungs and may make CT interpretation difficult.</p>	<p>Delay low-dose CT scan for 12 weeks from symptom resolution to avoid false positive results.</p> <p>Those presenting with symptomatic lung infections should be booked in for a deferred scan appointment in 12 weeks' time.</p> <p>Radiology service providers when considering the clinical appropriateness of low-dose CT requests must ask participants about symptomatic lung infection(s).</p> <p>Ask participants about any prior or proposed cancer surveillance CT study.</p>
<p>Full CT scan of the chest within last 12 months or planned for clinical reasons (for example, active cancer surveillance), in next 3 months.</p>	<p>Participant has already been screened for lung cancer and the low-dose CT will result in unnecessary additional radiation exposure.</p> <p>The National Lung Cancer Screening Program nodule management protocol, can be used to assess the risk of a lesion being a lung cancer and recommend appropriate surveillance or referral for management. It cannot assess the risk of that lung lesion being a metastasis in a high risk patient, nor be used to plan surveillance for those patients.</p>	<p>Delay low-dose CT scan by 12 months since full CT scan.</p>



Shared decision-making and informed choice

Summary – what will happen?

Shared decision-making enables people to make an **informed choice** about lung cancer screening and is an integral component of the program. Shared decision-making discussions should prioritise the creation of a trusting environment to ensure people feel safe to ask questions and openly discuss lived experiences and diverse needs (47).

Healthcare providers authorised to request a NLCSP low-dose CT, or healthcare providers working in collaboration with an authorised medical practitioner, can facilitate shared decision-making. Healthcare providers should support people to make an informed choice, even if they decide not to take part in the program.

How to implement – recommendations and practice points

A shared decision-making discussion follows three steps (78,79)

- **Choice talk** – helping people understand that a choice to screen exists.
- **Options talk** – informing people about their options.
- **Decision talk** – supporting people to decide if screening is right for them.

Making an informed choice

The information provided and discussed in a shared decision-making discussion forms the basis of an individual's **informed choice** to participate in screening. Providing accurate and clear information is one of the best ways to help people make an informed choice.

Healthcare providers should consider providing information on the following points when engaging in shared decision-making:

- The benefit of lung cancer screening is to find lung cancer as early as possible.
- The screening test is a low-dose CT scan.
- What is involved in lung cancer screening (e.g. what happens on the day of the scan, frequency of scans, who is involved).
- The low-dose CT scan will take place in a radiology service.
- Mobile screening may be an option for people living in some rural or remote areas.
- No preparation is required for a low-dose CT scan for lung cancer screening.
- Having a low-dose CT scan involves being exposed to a small amount of radiation.
- Most people will not be diagnosed with lung cancer.
- Some people will have an additional health finding that is not lung cancer.
- How and when people will receive their screening results.
- What happens if the results require further action.
- What happens if someone is diagnosed with lung cancer.
- Treatment options for lung cancer if diagnosed.
- The possible financial costs involved in receiving treatment for lung cancer.
- Psychosocial supports available.

Supporting shared decision-making

Shared decision-making resources have been developed to support healthcare providers to engage in shared decision-making discussions with potential screening participants. Both healthcare provider and participant-facing resources have been co-designed to support shared decision-making with Aboriginal and Torres Strait Islander peoples.

Shared decision-making resources can be accessed on the Australian Government Department of Health and Aged Care [National Lung Cancer Screening Program website](#).



DRAFTING NOTE: Materials to support shared decision-making are currently in development. Links to these materials will be included in the final Program Guidelines.

How information about the program is discussed with a person and the resources provided should be tailored to meet their needs and should foster collaboration and trust between them and their healthcare provider (80). This process is integral to establishing safe and respectful environments that can further facilitate informed choice and participation.

Tailoring the discussion involves considering:

- How the individual receives information (written, visual, verbal, video, use of interpreters, etc.).
- Who provides information to the individual.
- How much information is needed to inform choice.
- Who can support the individual to process information, including if family and/or community members should be invited to the discussion.

Practice Points

Shared decision-making: Engage in shared decision-making to support people to make an informed choice about lung cancer screening, even if they decide not to take part in the program.

Facilitation: Shared decision-making and consent processes can be facilitated by healthcare providers who either have the authority to request a low-dose CT scan, or healthcare providers (e.g., nurses, nurse practitioners, Aboriginal and Torres Strait Islander Health Workers or Practitioners) working in collaboration with authorised medical practitioners.

Discussion: Engage in a genuine discussion that is responsive to peoples' values, preferences, circumstances and information needs. Provide time and space for the individual to ask questions.

Inclusive: Ensure that shared decision-making is culturally appropriate and tailored to the individual person, with consideration of language, terminology, images, and accessibility. Use interpreters where appropriate.

Flexibility: Individuals may require flexible appointment structures to properly engage in shared decision-making. This may include having more than one consultation and/or involving the family/support network in the decision-making process.

Data privacy: Healthcare providers must provide the National Lung Cancer Screening Program privacy information document to all people who decide to participate in the program.

Smoking cessation: Smoking cessation supports should be offered to all individuals who currently smoke or who have recently quit.

Resources

For general audience – *in development*:

- A shared decision-making resource for Aboriginal and Torres Strait Islander people
- Shared decision-making materials for participants and their healthcare providers.

For healthcare providers – *in development*:

- A privacy information document which healthcare providers can provide to participants.
- A healthcare provider guide to support Aboriginal and Torres Strait Islander peoples to make an informed decision
- Shared decision-making materials for participants and their healthcare providers
- Conversation starters

Enrolment in the National Cancer Screening Register

Authorised medical practitioners are required to complete and send the Healthcare Provider Eligibility and Enrolment Form to the NCSR to enrol a participant in the program. Healthcare providers can complete the form and enrol a participant in the NCSR either through the NCSR interface integrated with clinical software or through the NCSR Healthcare Provider Portal.

Participants will receive welcome correspondence from the NCSR which will include information on why the low-dose CT scan is important, how to complete the low-dose CT scan, and how participants can opt-out of the NCSR if they wish to do so.

Assumed Consent

In line with other national cancer screening programs in Australia, the program has adopted an assumed consent model i.e. unless there is indication from participant or healthcare provider that the participant has opted out, the NCSR will assume the individual consents to the storage of their information as part of the program within the NCSR. For this reason, healthcare providers should record if a person chooses to decline to participate through the Healthcare Provider Eligibility and Enrolment form and in accordance with the NCSR privacy policy.

Opting out

Individuals can choose to opt-out of the NCSR and still have a free low-dose CT scan, however they will not be considered a participant of the program or receive communication from the NCSR. The radiologist will still be able to receive the rebate from Medicare.

If participant opts out of participating in the NCSR, it is the responsibility of the requesting authorised medical practitioner to notify participants of repeat or follow-up scans. Practice staff should regularly check the participant's contact details and update their practice records.

A participant's information (for example, the participants name, address, date of birth and Medicare number) will still be stored to ensure the NCSR does not collect any new clinical information about the participant. This information will not be used or disclosed outside of this purpose.

If a participant requires more information about the NCSR or wishes to change the way they interact with the NCSR they can visit the [Information for Participants on the NCSR website](#)

For more information visit the [NCSR website](#)

How to implement – recommendations and practice points



Practice Points

NCSR enrolment: Authorised medical practitioners are required to enrol participants in the NCSR – [CIS integration guide and GP enrolment guide](#)

NCSR enrolment: Participants can opt-out of enrolment in the NCSR at any time. If these individuals choose to continue screening using the program-specific MBS items, they will be considered external screeners (not participants) and will not be captured in the program reporting. Refer to the Key Definitions section for more information.



Resources

[NCSR privacy policy](#)

Low-dose CT scan request

Summary – what will happen?

Participants are screened for lung cancer by undergoing a low-dose CT scan performed by a radiographer. The low-dose CT scan is free for eligible people under Medicare. The cost of the low-dose CT scan is reimbursed to the radiology imaging provider by Medicare (81), provided there is a request from an authorised medical practitioner and the relevant rules are followed.

A summary of the steps leading up to the low-dose CT scan request is shown below in Table 4.

How to implement – recommendations and practice points

Authorised medical practitioners are required to complete a low-dose CT scan request as per usual practice for radiology imaging requests, once a participant has been checked for suitability to undergo a CT scan. The low-dose CT Scan request will need to identify that the low-dose CT scan is being requested for the National Lung Cancer Screening Program, and include family history of lung cancer and emphysema which will be needed by the radiologist reading and reporting on the scans using the National Lung Cancer Screening Nodule Management protocol.

Low-dose CT scan requests do not expire and are valid until the scan has been performed (82).

Table 3: Summary of requirements prior to screening at baseline and biennial / follow-up screening

	Baseline (first) screening	Biennial / follow-up screening
Eligibility Assessment	Yes	No <i>Once a participant is enrolled in the program, smoking eligibility does not need to be re-assessed. Need to confirm age eligibility.</i>
Suitability check for low-dose CT scan	Yes	Yes
Shared decision-making	Yes	Yes
Registration for program within the NCSR	Yes	No <i>Confirm participant information and contact details</i>
Low-dose CT scan request*	Yes	Yes

**requires participant to make an appointment to see an authorised medical practitioner to obtain the low-dose CT request*

Supporting participants

Participants should be advised to contact radiology services or medical imaging providers participating in the program to book a low-dose CT scan appointment as soon as possible after receipt of the low-

dose CT scan request. This may include providing assistance to the participant to book an appointment or identifying supports needed to book and complete the low-dose CT scan.

Mobile screening may be available for some rural and remote participants. Visit the [Heart of Australia](#) website for scheduling and booking information.



DRAFTING NOTE: The Department of Health and Aged Care is working with jurisdictions and their stakeholders, NACCHO and their affiliates and Heart of Australia to plan mobile screening service routes. Once available, service routes will be on the Heart of Australia website



Practice Points

Request: Complete a screening low-dose CT scan request and provide to participant. Low-dose CT scan request to specify 'lung cancer screening' and include family history of lung cancer and emphysema details, where applicable.

Assistance: Consider participant support and information needs in relation to accessing a low-dose CT scan, including mobile screening services and the participant travel support service for the program in rural and remote communities, accommodation, identifying a support person, family support, language proficiency/need for an interpreter, and eligibility for support services when booking an appointment.

DRAFT

Low-dose CT scan

Summary – what will happen?

Booking a low-dose CT scan appointment

Appointments with radiology services for low-dose CT scans need to be made in advance of the scan being performed.

Low-dose CT scans are available at private and public radiology services (including mobile services) ([see low-dose CT infrastructure](#)). Participants with a low-dose CT scan request should contact a participating radiology service to book an appointment. Participation in the program is open to all radiology services. As the radiology workforce is an accredited and regulated workforce, they do not require any further accreditation to deliver the program (NLCSP Quality Framework).



DRAFTING NOTE: The Department of Health and Aged Care is developing a Quality Framework to outline the approach to measure, monitoring and evaluating the program. The final Program Guidelines will link to the Framework.

Healthcare providers can support program participants to identify a participating radiology service and book a low-dose CT scan appointment.

Resources:

- For more information on mobile screening including service delivery routes please visit the [Heart of Australia](#) website.



DRAFTING NOTE: The Department of Health and Aged Care is working with jurisdictions and their stakeholders, NACCHO and their affiliates and Heart of Australia to plan mobile screening service routes. Once available, service routes will be on the Heart of Australia website

Low-dose CT scan performed

The program uses low-dose CT scans to look for lung cancer in high-risk people without any symptoms. As per the MBS item, radiographers and services should refer to current Royal Australian and New Zealand College of Radiologists (RANZCR) guidelines for appropriate low-dose CT dosage.

For the low-dose CT scan, participants will lie down on a table while the equipment takes images of their chest. It is a non-contrast low-dose CT scan. The scan does not involve any injections or other procedures, and usually takes around 10 to 15 minutes.



DRAFTING NOTE: The Royal Australian and New Zealand College of Radiology (RANZCR) is developing Low-Dose CT Image Acquisition Guidelines. These will be available on RANZCR's website and will be linked to from the Program Guidelines.



Resources

[RANZCR Standards of Practice for Clinical Radiology](#)

For general audience – *in development*:

- Visiting the radiology clinic (or mobile screening service)
- Low-dose CT scan video
- Frequently asked questions

For healthcare providers – *in development*:

- GP resource guide
- Frequently asked questions
- Supporting participants
- Screening and assessment pathway infographic with roles and responsibilities at each stage

How to implement – recommendations and practice points

New MBS items for NLCSP low-dose CT scans

Two new Medicare Benefit Schedule (MBS) items provide low-dose CT scans under the program. The MBS items are for:

- a. The screening low-dose CT scan undertaken every 2 years
- b. Follow-up low-dose CT scans for any follow-up needed during the 2-yearly screening period (as required following results of the screening low-dose CT scan).

These are mandatory bulk billing items and have mandatory reporting requirements.

The [MBS website](#) provides more information on these items, including the item descriptors and explanatory notes for the scan.

Radiology providers must bulk bill low-dose CT scans for the program when using the program-related MBS items. As a bulk-billed item, a radiology provider accepts the schedule fee as full payment for the service when claiming from MBS. This means participants will not have any out-of-pocket costs for the low-dose CT scan through the program.



DRAFTING NOTE: From July 2025, the MBS website will provide more information on these new items, including the item descriptors and explanatory notes. The final Program Guidelines will link to the MBS website.



Recommendations

MSAC: Radiology providers bulk bill low-dose CT scans for the program when using the NLCSP-related MBS items.



Practice Points

Scan quality: Radiographers will check the quality of the scan before the participant leaves the service. A poor quality scan may need to be repeated as soon as reasonably possible. If the scan needs to be redone the same MBS item and low-dose CT scan request is used.

Low-dose CT scan assessment and reporting

Summary – what will happen?

The timely and consistent assessment of low-dose CT scans and reporting results is critical to delivering a safe and effective lung cancer screening program.

The program uses a nationally standardised approach to ensure radiologists accurately and consistently read and report program low-dose CT scan results. Reports for a participant's baseline scan (the first scan when entering the screening program) and their follow-up scans (biennial repeat and follow-up scans) are read and reported using the National Lung Cancer Screening Program Nodule Management Protocol. The protocol has been developed by the Royal Australian and New Zealand College of Radiologists (RANZCR) and the Thoracic Society of Australia and New Zealand (TSANZ) [insert link to RANZCR website when available]. It applies the recommendations made by MSAC to the Australian setting and is available [here](#).



DRAFTING NOTE: The National Lung Cancer Screening Program Nodule Management Protocol is being finalised by the Department of Health and Aged Care with RANZCR and TSANZ and will be published along with the Program Guidelines before program commencement.

Radiologists are responsible for the supervision, interpretation and reporting of the low-dose CT scan (83). As the radiology workforce is an accredited and regulated workforce, they do not require any further accreditation to deliver the program (NLCSP Quality Framework). RANZCR has developed education modules on the program and use of the nodule management protocol (RANZCR education modules).



DRAFTING NOTE: RANZCR is developing education modules for the radiology sector on the program including the National Lung Cancer Screening Program Nodule Management Protocol. The education modules will be available on RANZCR's website and will be linked to in the Program Guidelines.

Nodule Management Protocol

The National Lung Cancer Screening Program Nodule Management Protocol contains detailed guidance for the radiologist around reporting lung nodule findings and providing appropriate management recommendations. The protocol is derived from:

- Pan-Canadian Early Detection of Lung Cancer (PanCan) risk calculator for reporting baseline scans (baseline nodule management) (11)
- Lung CT Screening Reporting & Data System (Lung-RADS®) for reporting follow-up scans, including biennial repeat and shorter interval follow-up scans (follow-up nodule management) (12).

The National Lung Cancer Screening Program Nodule Management Protocol contains separate baseline and follow-up nodule management guidance, with explanatory notes for radiologists to translate this guidance into the radiological interpretive environment. The Protocol will be available on the RANZCR website. The radiologist should use the most recent version of the nodule management protocol at the time of reporting. Nodule follow-up or investigation by the authorised medical practitioner should be undertaken according to radiological recommendation. The protocol will categorise participants into the appropriate risk category which will then determine what action is needed and the timeframe for action (see scan outcomes section).

Reporting results to the National Cancer Screening Register

Structured radiology reporting ensures a nationally standardised approach for radiologists to accurately and consistently report program low-dose CT scan results.

It is mandatory that low-dose CT scan reports are sent to the NCSR. The NCSR interacts and operates effectively with existing software and the structured reports will integrate with the NCSR. The low-dose CT scans (images) will not be stored in the NCSR; however, the NCSR stores information about where each scan is undertaken and reported to assist radiologists with locating previous images. Comparison to previous imaging (where available) by the radiologist is a critical element in safe and accurate radiological interpretation.

The information reported to the NCSR supports the delivery of the program. The NCSR provides information and helpful follow-up about screening, such as reminding participants and their healthcare provider, when they are due or overdue for lung cancer screening and when they need to take action after a scan.

Low-dose CT scan reports are required to be provided to the requesting medical practitioner through usual care arrangements for imaging reporting processes.



Recommendations

Baseline scans: Radiologists use the National Lung Cancer Screening Program Nodule Management Protocol guidance for reporting baseline scans (baseline nodule management table).

Subsequent scans: Radiologists use the National Lung Cancer Screening Program Nodule Management Protocol guidance for reporting biennial repeat and all follow-up scans (follow-up nodule management table).

Reporting: Radiologists use structured radiology reports to report all program low-dose CT scan results to the NCSR.



Practice Points

Reporting: Low-dose CT scan reports are provided to requesting medical practitioners through usual care arrangements for imaging reporting processes.



Resources

RANZCR Structured radiology report – *in development*

Results and next steps

Scan outcomes

Summary - what will happen?

Low-dose CT scan results will be classified into the following categories:

- Incomplete
- Very low risk
- Low risk
- Low to moderate risk findings
- Moderate risk
- High risk
- Very high risk
- Additional actionable finding.

The scan outcome category determines the participants journey through the screening and assessment pathway.

Scan outcome management

Scan outcomes are communicated to participants by healthcare providers as per usual care, with the support of the NCSR (see [Results communication](#)).

Incomplete findings require further action. If part, or all, of the lung cannot be evaluated, additional screening imaging is needed. If findings are suggestive of an inflammatory or infectious process,

participants return for a 1-, 2-, or 3-month low-dose CT scan; they will need to see their GP to get a new low-dose CT scan request.

Very low risk findings require no immediate action. Participants remain in the program and receive a reminder for a biennial repeat scan in 2 years.

Low risk, low to moderate risk, moderate risk, high risk, and very high risk findings require further action. Participants with low, low to moderate and moderate risk findings return for a follow-up low-dose CT scan at the interval specified in the nodule management protocol. Participants with high risk and very high risk findings are referred to a respiratory physician linked to a lung cancer multidisciplinary team (Figure 3 and Table 6). The practitioner managing the participant will make the referral to a respiratory physician.

Additional findings are potentially clinically significant or clinically insignificant findings unrelated to lung cancer (see Additional Findings section). These should be investigated as per usual care arrangements and do not preclude a participant from continuing in the program. The practitioner managing the participant will make referrals to specialists for further investigations.

DRAFT




Figure 3: Simplified nodule management protocol flowchart

How to implement – recommendations and practice points

A biennial repeat screen is the standard screening interval for the program. A participant will screen biennially (every two years) if they have very low risk findings.

A summary of low-dose CT scan outcome categories and further action required by the participant is provided in Table 7.

Table 4: Summary of scan outcomes and further action required by the participant

Category descriptor	Next steps
Incomplete - findings suggestive of an inflammatory/infectious process	<ul style="list-style-type: none"> Continue in program. Receive a recall from radiologist for follow-up scan in 1-, 2- or 3-months. Make an appointment to see an authorised medical practitioner to obtain a low-dose CT scan request.
Incomplete - part or all of lung cannot be evaluated (additional screening imaging needed)	<ul style="list-style-type: none"> Continue in program Recalled by radiology clinic for low-dose CT scan under existing low-dose CT request.
Very low risk	<ul style="list-style-type: none"> Continue in program. Receive a reminder for biennial repeat screening Make an appointment to see an authorised medical practitioner to obtain a low-dose CT scan request.
Low risk	<ul style="list-style-type: none"> Continue in program. Receive correspondence advising to see healthcare provider See their HCP to discuss results Receive a reminder for a follow-up scan in 12-months . Make an appointment to see an authorised medical practitioner to obtain a low-dose CT scan request.
Low to moderate risk	<ul style="list-style-type: none"> Continue in program. Receive correspondence advising to see healthcare provider See their HCP to discuss results Receive a reminder for a follow-up scan in 6-months . Make an appointment to see an authorised medical practitioner to obtain a low-dose CT scan request.
Moderate risk	<ul style="list-style-type: none"> Continue in program. Receive correspondence advising to see healthcare provider See their HCP to discuss results Receive a reminder for a follow-up scan in 3-months . Make an appointment to see an authorised medical practitioner to obtain a low-dose CT scan request.
High risk	<ul style="list-style-type: none"> Receive correspondence advising to see healthcare provider immediately and HCP contacts to make appointment. See their HCP to discuss results Referred to a respiratory physician linked to a lung cancer multidisciplinary team (MDT). Remain in program whilst investigations are underway.

Very high risk	<ul style="list-style-type: none"> • Receive correspondence advising to see healthcare provider immediately and HCP contacts to make appointment. • See their HCP to discuss results • Referred to a respiratory physician linked to a lung cancer multidisciplinary team (MDT). • Remain in program whilst investigations are underway.
Actionable additional finding	<ul style="list-style-type: none"> • Receive correspondence advising to see healthcare provider. • See their HCP to discuss results • Actionable additional findings investigated according to relevant clinical guidelines and usual care arrangements. • Refer to Additional findings and Program exit and re-entry sections to understand whether the participant will remain in the program or whether they will exit/pause participation in the program.

Referral pathways for high risk or very high risk findings

The investigation of screen-detected abnormalities falls outside of the program and is part of usual care and existing clinical guidance, including the [Optimal Care Pathway \(OCP\) for People with Lung Cancer](#) (84). Participants with high risk or very high risk findings will be referred by their healthcare provider to a respiratory physician linked to a lung cancer multidisciplinary team for clinical investigation.

The [tumour, node and metastasis \(TNM\) system](#) involves various tests, including but not limited to pathology and histology tests, which specialists use to stage lung cancer (85). If lung cancer is diagnosed, specialists should update the NCSR with test findings using the Diagnosis Form. If this data has not been entered within 4 weeks since date of specialist referral, the NCSR will follow up with the specialist or the participants nominated/authorised medical practitioner. Histopathology reports will be transmitted automatically from integrated laboratories to the NCSR to support program monitoring and reporting.



Practice Points

NCSR: Medical practitioners to enter findings from all tumour, node and metastasis (TNM) system tests to the NCSR using the Diagnosis Form within the appropriate clinical timeframe to ensure participants receive appropriate screening reminders or exit the program in lung cancer is diagnosed.

Additional findings

Summary – what will happen

As imaging of the chest is not limited to findings that may be lung cancer, other findings in the thorax, the upper abdomen and the lower neck are common.

Additional findings on low-dose CT scans occur on a continuum from benign to life threatening. Minor and clinically insignificant additional findings are common on low-dose CT scans and have the potential to cause unnecessary investigations and anxiety to participants. Therefore, these findings will not be reported in the structured radiology report. The low-dose CT scan is an opportunity to detect and manage actionable additional findings beyond lung cancer which may be a benefit for the participant. Actionable additional findings have been defined by guidance developed by RANZCR.

Clear guidance and concise recommendations on how to manage additional findings in a standardised way in the implementation of the program is critical. It is important that emphasis is placed on reporting of additional findings that are clinically significant and where there are interventions for participant benefit.

The scope of the program does not include the clinical investigation of non-lung nodule screen-detected abnormalities (additional findings) or the diagnosis of lung cancer or other conditions such as cardiovascular related conditions. Participants with actionable additional findings will be managed as per the RANZCR Additional Findings Guidelines for the National Lung Cancer Screening Program.



DRAFTING NOTE: RANZCR is developing Additional Findings Guidelines. The Additional Findings Guidelines will be published along with the Program Guidelines before program commencement.

Referring medical practitioners should consider management recommendations from the RANZCR Additional Guidelines when considering next steps for a participant with actionable additional findings. Management should occur as per usual care arrangements, clinical judgement and relevant clinical guidelines.

How to implement – recommendations and practice points

Additional findings will be managed outside the program according to the relevant clinical guidelines.

Clinically significant additional findings will be documented in the NLCSP structured radiology report. The RANZCR Additional Findings Guidelines for the National Lung Cancer Screening Program provides radiologists with follow-up recommendations. Clinically significant findings will be reported to the NCSR and will inform program monitoring and evaluation.

Referring authorised medical practitioners will be informed of actionable additional findings with further action required and will be responsible for managing the findings according to relevant clinical guidance.



Practice Points

Documentation: All clinically significant additional findings are documented in the NLCSP structured radiology report and include a follow-up recommendation for any actionable findings.

Reporting: Clinically significant findings are reported to the NCSR to inform program monitoring and evaluation.

Management: Requesting practitioners will be informed of additional findings with further action required and will be responsible for managing the findings according to relevant clinical guidelines.



Resources

For general audience – *in development*:

- Understanding results
- Understanding lung nodules and additional findings
- About lung cancer
- Frequently asked questions

For healthcare providers – *in development*:

- GP resource guide
- Frequently asked questions
- Supporting participants
- Communicating lung cancer and reducing stigma
- Screening and assessment pathway infographic with roles and responsibilities at each stage

Results communication

Role of requesting authorised medical practitioner

If the requesting authorised medical practitioner is a medical specialist or consultant, they can engage the participants' primary healthcare provider to support communication of scan results, by facilitating a timely and appropriate clinical handover. Participants may nominate an alternate recipient of their communication (e.g. an ACCHO) in situations where they may not have a regular GP i.e. where locum GPs are relied upon.

Authorised medical practitioners are advised to manage results communication according to usual care, including for additional findings. Cancer screening participants are known to prefer verbal communication when receiving screening results, particularly for findings with further action required (66).

For participants who cease receiving communication from the NCSR, they will not have this communication safety net. All communications with the participant of scan results will be the responsibility of the requesting authorised medical practitioner.

Effective and high-quality communication of screening results is critical to:

- Participants' understanding of what their results mean for their health
- Minimising participant distress or anxiety
- Supporting participants through the follow-up pathway and minimise loss to follow-up
- Fostering culturally safe and respectful health care environments, especially for priority populations.

Role of the NCSR

Screening outcomes need to be communicated to the participant in a timely and culturally safe manner. For participants registered in the NCSR, the process of communicating next steps is also supported by the NCSR which provides immediate correspondence (Figure 5 and Table 9).

Table 95: Summary of NCSR results communication responsibility and recipient

NLCSP correspondence from NCSR		Recipient
Risk category	Participant	Medical practitioner
Incomplete (part or all lung cannot be evaluated)	Radiology clinic to recall participant directly – scan will be covered by the existing low-dose CT request form	
Incomplete (findings suggestive of an inflammatory or infectious process)	Notified to contact requesting practitioner	Notified to contact participant
Very low risk	Notified of very low risk findings and to rescreen biennially	Notified of very low risk findings and to rescreen biennially
Low risk	Notified to contact requesting practitioner	Notified to contact participant
Low to moderate risk	Notified to contact requesting practitioner	Notified to contact participant
Moderate risk	Notified to contact requesting practitioner	Notified to contact participant
High risk	Notified to contact requesting practitioner	Notified (via phone call and correspondence) to contact participant
Very high risk	Notified to contact requesting practitioner	Notified (via phone call and correspondence) to contact participant
Additional actionable finding	Notified to contact requesting practitioner	Notified to contact participant

The NCSR will notify the participant and the requesting practitioner when results are available and facilitate screening reminders (Figure 5).

The NCSR supports the program by acting as a communication safety net by prompting participants and their healthcare providers to undertake any required follow-up action. NCSR communication does not replace the duty of care responsibilities that healthcare providers have for communicating with and managing participants.

Participants can select their communication mode preference in the NCSR participant portal i.e. posted mail, email or SMS text message.

Healthcare providers can ask participants about their preferred method of communication from the NCSR upon enrolment to the program and update their information as appropriate and encourage participants to access the NCSR portal via MyGov.

Results communication responsibilities




Figure 4: Simplified results communication process and responsibilities

Results communication and lung cancer risk

All communication with participants should be sensitive to the likelihood of “scan anxiety” (86). Healthcare providers should ensure psychosocial support is available and should be aware of services which are tailored to specific priority populations.

Healthcare providers are to accommodate participants’ communication preferences regarding how and when is appropriate to discuss their results, including if multiple consultations or support persons are needed. Participants should be provided with accurate and clear information about what their results mean and what follow-up is required.

The approach taken to communicate results will vary depending on the scan result and corresponding risk level. Healthcare providers should discuss the next steps involved and consider any support that may be needed to facilitate participant continuation in screening.

The [International Association for the Study of Lung Cancer \(IASLC\) Language Guide](#) is an important resource for conversing with participants throughout the pathway, including when communicating results (87).



Practice Points

Communication: Participants are notified by the NCSR that their results are available. Screening results to be communicated by the healthcare provider to the participant as per usual care.

Clarity: Healthcare providers should ensure that information is clear, and that the participant understands what their results mean. This may mean having more than one consultation and involving family and support networks as appropriate.

Sensitivity: All communication should be strengths-based, person-centred and delivered under the principle of ‘treat the person not the illness’. Providers can consult the [IASLC Language Guide](#) for guidance.

Smoking cessation: Smoking cessation follow-up support should be offered to all individuals who currently smoke or who have recently quit.

Communicating results to Aboriginal and Torres Strait Islander peoples

It is the responsibility of all healthcare providers to provide culturally safe care to program participants.

It is critical that Aboriginal and Torres Strait Islander participants and their families and/or communities can make self-determined decisions about their participation in the program.

Healthcare providers can support this by fostering culturally safe environments and tailoring their usual care practice to be person-centred (incorporating family and cultural roles) (88,89), strengths-based and responsive to the needs of the participant. This may include:

- Offering multiple appointments to discuss scan results and what they mean for the participant. This includes making space and time for family and/or support people to attend and support the participant.

- Enabling multiple family members and/or support people to attend appointments to discuss results in person or remotely.
- Taking time to build rapport with the participant to establish a safe space for clarifications and questions. Healthcare providers should ensure that the participants understand what is being communicated.
- Using Aboriginal and Torres Strait Islander co-designed and/or tailored resources to aid in the communication of results and any follow-up discussions. Cancer Council provides a repository of relevant [cancer fact sheets and resources for Aboriginal and Torres Strait Islander people](#) (90).
- Communication of results by an authorised medical practitioner could occur via a telehealth appointment. For rural and remote participants, it may be important to consider communication of results via telehealth (if eligible).

Healthcare providers can consult [appropriate resources](#) (91) for effective communication with Aboriginal and Torres Strait Islander peoples in health settings.



Practice Points

Psychosocial support: Participants should be provided with clear and appropriate information about existing psychosocial services and supports. Healthcare providers should be attentive to the presence or development of psychological distress. This includes the distress of participants in the program, their supports, and/or their family members.

Information processing: Healthcare providers should be mindful that the emotional distress associated with receiving information about a positive result may temporarily impair a participant's capacity to process and understand the result. Reiterate the information and check that the participant has clearly understood.

Stigma: All results should be communicated without judgement, blame, or stigma.

Cultural safety: Ensure a culturally safe environment is provided for participants. When communicating scan results to Aboriginal and Torres Strait Islander participants, healthcare providers should communicate effectively and respectfully.

Sensitivity: Efforts to establish rapport with the participant (and any support persons present) are critical to creating a safe space for individuals to ask for clarifications and to ask questions.

Additional support: Healthcare providers can refer to the Cancer Council information and support line (13 11 20) which delivers a comprehensive range of support services for all people, affected by all cancers, across every state and territory.



Resources

For general audience – *in development*:

- Understanding results
- Understanding lung nodules and additional findings
- About lung cancer

For healthcare providers – *in development*:

- GP resource guide
- Frequently asked questions
- Supporting participants
- Communicating lung cancer and reducing stigma
- Screening and assessment pathway infographic with roles and responsibilities at each stage

Screening reminders

Summary - what will happen?

Biennial repeat and follow-up scan reminders will be issued by the NCSR in line with the participant's chosen communication method.

The NCSR will send screening reminders directly to participants via their preferred method (posted mail, email, or SMS) and to the requesting authorised medical practitioner (or recorded primary healthcare provider), who can help support and facilitate continued participation in the program.

How to implement – recommendations and practice points

Healthcare providers are encouraged to send practice-branded and/or tailored screening reminders to participants whose participation is recorded in their EMR system.

Personalised reminders can minimise loss to follow up by encouraging participants to stay engaged in the program and return for screening at the recommended follow-up time interval. Healthcare providers are advised to adapt their existing recall and reminder systems to align with the program screening schedule, including biennial repeat scans at 2-years, and follow-up scans (at 3-, 6- or 12-months).

The participants' requesting authorised medical practitioner is responsible for:

- Facilitating an appointment to re-complete a low-dose CT scan suitability check.
- Providing a low-dose CT scan request for biennial repeat screening and follow-up scans.

The NCSR will manage screening reminders following participant enrolment. A participant receives a notification from the NCSR as per the information provided in Table 9.

For participants who have elected not to receive communication from the NCSR, they should receive reminders and follow-up notifications from their referring authorised medical practitioner when:

- They are due for their biennial repeat screening or follow-up scan and need to return to their GP/authorised medical practitioner for a low-dose CT request.

- They have not yet actioned a low-dose CT scan request and/or have not actioned the required follow-up tests following the results of a low-dose CT scan.



Practice Points

Practice reminders: Healthcare providers are encouraged to send screening reminders directly to participants. The mode through which healthcare providers remind their clients will be specific to their practice or clinic and their own procedures (e.g. SMS or email) (92).

Next steps: Authorised medical practitioners are required to re-check suitability for all low-dose CT scans and provide a new low-dose CT scan request when a participant is due for biennial repeat screening or follow-up scans.

NCSR: The NCSR will send participants screening reminders. For participants who have opted out of NCSR communication, requesting authorised medical practitioners are responsible for sending screening reminders.

Program exit and re-entry

Summary - what will happen?

Participants may exit the program at any time. There are many reasons participants may exit the program, including for medical reasons, such as a cancer diagnosis, or being no longer able to undergo a CT scan. Participants may also actively opt out of the program, or may exit as they reach the upper age limit of the program. It is important that, upon exit of the program, individuals continue to be managed according to usual care from their healthcare provider as they may still be at risk of developing lung cancer. Eligible participants who have exited the program (unless they have aged out, e.g. 71 years of age) can re-enter and receive a low-dose CT scan request following confirmation of low-dose CT scan suitability.

Participants may not respond to reminders, which is known as lapsed screening. Reminders will continue to be sent, in particular for the biennial scans. Additionally, participants can choose to defer their next screen or pause screening reminders for a period (refer to Table 1).

Upon exit from the program (if aged out, opts-out or has a diagnosis of lung cancer), participants will be advised through the NCSR and/or their healthcare provider that their existing information in the NCSR will remain, but they will not receive further communications. If deceased, the NCSR will be contacted by Services Australia in this scenario and all correspondence will cease.

NCSR communication is provided via the participant's communication preference,.

Deferring or pausing participation

A participant can request to change or defer the date of their next screening. They can also request to pause or change their preference for participating in the program for a defined period.

These requests can be updated or cancelled at any time via the [Participant Portal](#), submission of a webform, or via calling the NCSR on 1800 627 701.

How to implement – recommendations and practice points

Age

The NCSR will notify participants if they exit the program due to their age (notification will occur at the end of the screening round in which they have turned 71 years).

Healthcare providers are advised to discuss options for ongoing monitoring and investigation outside of the program if the person becomes symptomatic. Healthcare providers are also advised to continue to offer smoking cessation support, if applicable, following a participant's exit from the program.

Diagnosis

Participants who exit the program due to being diagnosed with lung cancer should be managed according to usual care practices including the lung cancer optimal care pathway.

Program re-entry

There are some points that enable re-entry into the program. These include if a participant:

- Has previously opted out of the program, remains eligible and decides to re-enter the program
- Became unwell while participating in the program and had to exit. Now recovered and eligible to continue.

To re-enter the program participants should have their **age** eligibility re-confirmed, have no signs or symptoms suggestive of lung cancer, and suitability for low-dose CT scan checked. They will also need to re-engage in shared decision-making and make an informed choice to participate.



Practice Points

Screening duration: Participants should be given every opportunity to screen in accordance with the Program Guidelines until the participant is no longer eligible to participate, or until they opt-out of participation in the program.

Program exit: A participant with a high risk or very high risk nodule will exit the program and be referred to and managed according to the LC-OCP. Participants who exit the program due to symptomatic ineligibility will be monitored according to usual care.

Referral for investigation: If a participant has a high risk nodule finding or suspected lung cancer, the authorised medical practitioner should refer them to a respiratory physician linked to a lung cancer MDT.

Ageing out: Healthcare providers and/or the NCSR should inform participants at the end of the screening round in which they have turned 71 years of age that they are no longer eligible for the program. Upon exit, the participant's healthcare provider should discuss broader options.

Re-entry: Participants seeking to re-enter the program need to only meet the **age** eligibility criterion and have no signs or symptoms suggestive of lung cancer. Check for low-dose CT suitability and re-engage in a shared decision-making discussion.

Psychosocial support: Healthcare providers to offer tailored psychosocial support options and/or services to participants where appropriate. Program exit may cause people distress.

Smoking cessation: Smoking cessation support should be offered to all individuals who currently smoke or who have recently quit.

DRAFT

Key definitions

Additional actionable findings on lung cancer screening are defined as low-dose CT scan findings unrelated to the primary purpose of identifying lung cancer for which follow-up action is required (93).

Asymptomatic: for the purposes of the program, asymptomatic is defined as having no signs or symptoms suggestive of lung cancer (for example unexplained persistent cough, coughing up blood, shortness of breath).

Authorised Medical Practitioners are medical practitioners authorised to request low-dose CT scans as part of the National Lung Cancer Screening Program and include general practitioners, medical specialists and consultant physicians.

Baseline scan: is the first scan a participant has as part of the program.

Biennial repeat screening is the standard screening interval of the National Lung Cancer Screening Program. A participant screens biennially (i.e. every 2 years) if their low-dose CT scan outcome has no significant or very low risk findings.

Ceasing correspondence from the National Cancer Screening Register does not opt the participant out of the program. A participant may choose not to receive correspondence or defer correspondence from the National Cancer Screening Register. However, they still consent to their screening information being provided to the register. The participant and authorised medical practitioner become responsible for screening reminders and follow-up.

Cultural safety: Culturally safe practice is the ongoing critical reflection of health practitioner's knowledge, skills, attitudes, practising behaviours and power differentials in delivering safe, accessible, and responsive healthcare free of racism. Cultural safety is determined by Aboriginal and Torres Strait Islander individuals, families and communities (32).

Eligibility Assessment: An assessment of whether individuals meet the National Lung Cancer Screening Program eligibility criteria and qualify for participation in the program.

Follow-up scan is an interval low-dose CT scan that a participant is required to have there is a low, low to moderate, or moderate risk nodule finding on the baseline scan. Follow-up scan intervals are based on the risk category of the scan outcome.

Healthcare providers are any health provider working across primary, secondary, and tertiary healthcare settings. They are integral for the recruitment and delivery of the National Lung Cancer Screening Program but are not all authorised to request a National Lung Cancer Screening Program low-dose CT scan. *A summary of healthcare provider roles and responsibilities can be found in Table 2.*

Healthcare support workers are those who play a vital role in health care teams and provide support to people across the screening and assessment pathway.

High risk individuals are the potential participants in the National Lung Cancer Screening Program who meet the eligibility criteria for the program.

Low-dose computed tomography scan referred to hereafter as **low-dose CT scan** is the diagnostic imaging scan used to look for nodules in the lung that may indicate lung cancer.

Low-dose CT scan request is the form (hard copy or electronic) issued by a medical practitioner who is authorised to request the National Lung Cancer Screening Program low-dose CT scan.

Low-dose CT scan reporting is the reading and interpretation of low-dose CT scan results. This is also referred to as the assessment or evaluation of results, which may include computer-aided detection and other approaches to analysis.

Low-dose CT scan suitability for the National Lung Cancer Screening Program involves assessing whether individuals are suitable for screening low-dose CT based on their general health alongside factors relating to a person's ability to physically use CT scanners. An Authorised Medical Practitioner assesses low-dose CT suitability to ensure the scan is clinically appropriate.

Multidisciplinary teams comprise the core disciplines that are integral to providing good care. The team is flexible in approach, reflects the patient's clinical and psychosocial needs and has processes to facilitate good communication.

National Cancer Screening Register: The NCSR provides a single electronic record for each person participating in cancer screening programs, and provides a national electronic infrastructure for the collection, storage, analysis and reporting of screening program data. The NCSR will provide program information and reminders to participants. It will not hold the scan images. Relevant healthcare providers may access participant information and remind them if they need to take action in relation to lung cancer screening.

National Lung Cancer Screening Program referred to as the **program** is the formal title for the National Lung Cancer Screening Program in Australia.

Opt-out of the NCSR means to opt-out of the program, an eligible person will become an external screener (see definition of a **Participant**) if they use the National Lung Cancer Screening Program MBS items, or they may cease screening all together. There are two ways to opt-out of the NCSR:

- Opt-out of the NCSR from the start: the external screener does not consent to their screening information being held in the NCSR and therefore they are never enrolled.
- Opt-out from the NCSR after being a participant: the individual who previously consented to their screening information being provided to the NCSR withdraws this consent and is no longer a program participant. Their existing data remains in the NCSR but is not viewable. A former participant can view the data by calling the NCSR Call Centre. However no new data will be provided to the NCSR if the individual becomes an external screener.
- In both situations, the participant and authorised medical practitioner are responsible for screening reminders and follow-ups if the individual becomes an external screener.
- Opting-out of the NCSR is not the same as **ceasing correspondence** (refer to definition).
- An individual can opt-in to the NCSR any time.

Pack-years is a way of measuring the number of cigarettes a person has smoked in their lifetime. Pack-years are calculated by multiplying the number of packs of cigarettes (approximately 20 individual cigarettes) smoked per day by the total number of years a person has smoked.

Participant refers to an eligible person registered as part of the National Lung Cancer Screening Program through the National Cancer Screening Register.

- **External screeners** are eligible people who choose not to register for the National Lung Cancer Screening Program through the National Cancer Screening Register. They are not considered a participant of the program as there is no other mechanism to monitor their participation.
- These individuals are able to use the program MBS items but will not be captured in program reporting. The authorised medical practitioner is responsible for screening and results communications.
- The Program Guidelines do not refer to external screeners as they are not participants of the program, but nodule management protocols should be used to guide their screening pathway.
- This approach aligns with the National Bowel Cancer Screening Program and the National Cervical Screening Program within the National Cancer Screening Register.

Program exit refers to when a participant exits the screening program by having a lung cancer diagnosis, opting out or reaching the National Lung Cancer Screening Program upper age limit of 70 years (age ineligibility).

Program re-entry refers to when an eligible participant re-enters the National Lung Cancer Screening Program after previously exiting the program for any reason (excluding the upper age limit of 70 years).

Recruitment refers to the way in which potentially eligible participants are identified and recruited to participate in the National Lung Cancer Screening Program.

Results communication is defined as the process of sharing the low-dose CT scan results with program participants and their requesting practitioner(s).

Screening reminders are notifications sent by the National Cancer Screening Register to the program participant and the requesting authorised medical practitioner to remind participants they are due for lung cancer screening.

Shared decision-making involves discussion to foster collaboration and trust between a participant and their health care provider, with a goal to empower participants to be actively involved in their health care. It is about aligning the participant's values, preferences and circumstances with the best available evidence about the available options, their benefits and harms, and uncertainties of treatment to make the most appropriate and informed health care decision for that person (94–96). Shared decision-making is a person-centred process that enables people to feel safe and trusted to make informed decisions based on their values, beliefs, and understanding.

Smoking, in the context of the National Lung Cancer Screening Program, refers to cigarette tobacco smoking only and does not include the use of other combustible tobacco products, including vapes or e-cigarettes.

Smoking cessation is the stopping or quitting of smoking cigarettes or other combustible tobacco products (e.g. cigars, cigarillos, pipes, and shisha). Smoking cessation support refers to assistance given to someone to help them quit smoking. Cessation support should also be offered to people who use

vapes or e-cigarettes, noting that tobacco products in the context of the National Lung Cancer Screening Program does not includes vapes or e-cigarettes.

DRAFT

Glossary

Term	Definition
ACCHO	Aboriginal Community Controlled Health Organisation
AMS	Aboriginal Medical Service
ANZSTR	Australian and New Zealand Society of Thoracic Radiology
Ahpra	Australian Health Practitioner Regulation Agency
ATSIHPBA	Aboriginal and Torres Strait Islander Health Practice Board of Australia
CALD	Culturally and linguistically diverse
ECOG	Eastern Cooperative Oncology Group
EMR	Electronic Medical Record
GP	General Practitioner
IASLC	International Association for the Study of Lung Cancer
LC-OCP	Lung Cancer - Optimal care pathway for people with lung cancer
LGBTIQ+	Lesbian, Gay, Bisexual, Transgender, Intersex, Queer and Asexual people
Low-dose CT	Low-dose computed tomography
Lung-RADS	Lung Imaging Reporting and Data System
MBS	Medical Benefit Schedule
MDT	Multidisciplinary team
MSAC	Medical Services Advisory Committee
NACCHO	National Aboriginal Community Controlled Health Organisation
NCSR	National Cancer Screening Register
NLCSP	National Lung Cancer Screening Program
OCP	Optimal Care Pathway
PanCan	Pan-Canadian Early Detection of Lung Cancer
QOL	Quality of life
RACGP	Royal Australian College of General Practitioners
RANZCR	Royal Australian and New Zealand College of Radiologists
SMS	Short message service
TIS	Tackling Indigenous Smoking
TNM	Tumour, nodule, metastasis staging
TSANZ	Thoracic Society of Australia and New Zealand

References

1. Australian Institute of Health and Welfare. Australia's health 2024: in brief [Internet]. Australian Government; 2024 [cited 2024 Aug 8]. Available from: <https://www.aihw.gov.au/reports/australias-health/australias-health-2024-in-brief/formats>
2. Australian Institute of Health and Welfare. Cancer data in Australia [Internet]. Australian Government; 2024 Aug [cited 2024 Aug 27]. Report No.: CAN 122. Available from: <https://www.aihw.gov.au/reports/cancer/cancer-data-in-australia/contents/about>
3. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. *The Lancet*. 2018 Mar;391(10125):1023–75.
4. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TML, Myklebust TÅ, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. *Lancet Oncol*. 2019 Nov;20(11):1493–505.
5. Australian Institute of Health and Welfare. Cancer in Australia 2021 [Internet]. Canberra, Australia: Australian Institute of Health and Welfare; 2021. Available from: <https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary>
6. Cancer Australia. Tobacco [Internet]. c2024 [cited 2024 Mar 28]. Available from: https://www.canceraustralia.gov.au/resources/position-statements/lifestyle-risk-factors-and-primary-prevention-cancer/lifestyle-risk-factors/tobacco#_ENREF_35
7. Department of Health and Aged Care. National Preventive Health Strategy 2021–2030 [Internet]. Australian Government; 2021 [cited 2024 Oct 15]. Available from: <https://www.health.gov.au/resources/publications/national-preventive-health-strategy-2021-2030?language=en>
8. Laaksonen MA, Canfell K, MacInnis R, Arriaga ME, Banks E, Magliano DJ, et al. The future burden of lung cancer attributable to current modifiable behaviours: a pooled study of seven Australian cohorts. *Int J Epidemiol* [Internet]. 2018 Dec 1 [cited 2024 Sep 12];47(6):1772–83. Available from: <https://doi.org/10.1093/ije/dyy136>
9. Medical Services Advisory Committee. 1699 – National Lung Cancer Screening Program Public Summary Document [Internet]. Canberra, Australia: Australian Government Department of Health; 2022 Jul [cited 2024 Mar 28]. Report No.: 1699. Available from: <http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1699-public>
10. Cancer Australia, Australian Government. Treatment options [Internet]. 2023 [cited 2024 Oct 9]. Available from: <https://www.canceraustralia.gov.au/cancer-types/lung-cancer/treatment>
11. McWilliams A, Tammemagi MC, Mayo JR, Roberts H, Liu G, Soghrati K, et al. Probability of cancer in pulmonary nodules detected on first screening CT. *N Engl J Med* [Internet]. 2013 Sep 5;369(10):910–9. Available from: <https://doi.org/10.1056/nejmoa1214726>
12. American College of Radiology, Christensen J, Prosper AE, Wu CC, Chung J, Lee E, et al. ACR Lung-RADS v2022: Assessment Categories and Management Recommendations. *J Am Coll Radiol* [Internet]. 2024 Mar 1 [cited 2024 Aug 28];21(3):473–88. Available from: [https://www.jacr.org/article/S1546-1440\(23\)00761-5/fulltext?_gl=1*17sg9p8*_ga*MjA4NDAwMzU5NS4xNzA4NDc1NzA2*_ga_K9XZBF7MXP*MTcyNDgyMTY0MS41LjEuMTcyNDgyMTc1Mi4wLjAuMA..](https://www.jacr.org/article/S1546-1440(23)00761-5/fulltext?_gl=1*17sg9p8*_ga*MjA4NDAwMzU5NS4xNzA4NDc1NzA2*_ga_K9XZBF7MXP*MTcyNDgyMTY0MS41LjEuMTcyNDgyMTc1Mi4wLjAuMA..)
13. Cancer Australia. Report on the Lung Cancer Screening Enquiry [Internet]. NSW, Australia: Australian Government; 2020 [cited 2024 Mar 28] p. 1–40. Report No.: 978-1-74127-356-4. Available from: https://www.canceraustralia.gov.au/sites/default/files/publications/report-lung-cancer-screening-enquiry/pdf/report_on_the_lung_cancer_screening_enquiry_0.pdf
14. Australian Government Department of Health and Aged Care. About the National Lung Cancer Screening Program [Internet]. Australian Government Department of Health and Aged Care; 2024 [cited 2024 Jun 23]. Available from: <https://www.health.gov.au/our-work/nlcsp/about>

16. Australian Government Department of Health and Aged Care. Establishing the National Lung Cancer Screening Program [Internet]. Australian Government Department of Health and Aged Care; 2024 [cited 2024 Jun 23]. Available from: <https://www.health.gov.au/our-work/nlcsp/establishing-program>
17. Australian Institute of Health and Welfare. BreastScreen Australia monitoring report 2019 [Internet]. Canberra, Australia: Australian Institute of Health and Welfare; 2019 [cited 2024 Feb 15]. Available from: <https://nla.gov.au/nla.obj-2309780820>
18. Cancer Council Australia. Cancer doesn't discriminate by culture - nor should we [Internet]. 2012 [cited 2024 Mar 28]. Available from: <https://www.cancer.org.au/blog/cancer-doesnt-discriminate-by-culture-nor-should-we>
19. Tosetti I, Kuper H. Do people with disabilities experience disparities in cancer care? A systematic review. PLOS ONE [Internet]. 2023 Dec 13 [cited 2024 Mar 28];18(12):e0285146. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10718463/>
20. Victorian Government Equality Team. LGBTIQ+ inclusive language guide [Internet]. Department of Families, Fairness and Housing; 2023 [cited 2024 Aug 28]. Available from: <https://www.vic.gov.au/inclusive-language-guide>
21. Crenshaw K. Mapping the Margins: Intersectionality, Identity Politics, and Violence against Women of Color. Stanford Law Rev [Internet]. 1991 [cited 2024 Jun 19];43(6):1241–99. Available from: <https://www.jstor.org/stable/1229039>
22. Australian Institute of Health and Welfare. National Bowel Cancer Screening Program Monitoring Report 2019. [Internet]. Canberra, Australia: Australian Institute of Health and Welfare; 2019 [cited 2024 Feb 15]. Available from: <https://www.aihw.gov.au/reports/cancer-screening/national-bowel-cancer-screening-program-monitoring/summary>
23. Australian Institute of Health and Welfare. National Cervical Cancer Screening Program Monitoring Report 2019. [Internet]. Canberra, Australia: Australian Institute of Health and Welfare; 2019 [cited 2024 Feb 15]. Available from: <https://www.aihw.gov.au/reports/cancer-screening/national-cervical-screening-monitoring-2019/data>
24. Australian Institute of Health and Welfare. Cancer in Aboriginal and Torres Strait Islander People of Australia. [Internet]. Canberra, Australia: Australian Institute of Health and Welfare; 2018 [cited 2024 Feb 15]. Available from: <https://www.aihw.gov.au/reports/cancer/cancer-in-indigenous-australians/contents/summary>
25. Brown A, Garvey G, Rankin NM, Nightingale C, Whop LJ. Lung cancer screening for Aboriginal and Torres Strait Islander peoples: an opportunity to address health inequities. Med J Aust [Internet]. 2023 Sep 11 [cited 2024 Feb 26]; Online first. Available from: <https://www.mja.com.au/journal/2023/219/9/lung-cancer-screening-aboriginal-and-torres-strait-islander-peoples-opportunity>
26. Thurber KA, Banks E, Joshy G, Soga K, Marmor A, Benton G, et al. Tobacco smoking and mortality among Aboriginal and Torres Strait Islander adults in Australia. Int J Epidemiol [Internet]. 2021 Jan 25 [cited 2024 Aug 28];50(3):942–54. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8271186/>
27. Maddox R, Thurber KA, Calma T, Banks E, Lovett R. Deadly news: the downward trend continues in Aboriginal and Torres Strait Islander smoking 2004–2019. Aust N Z J Public Health [Internet]. 2020 Dec;44(6):449–50. Available from: <https://pubmed.ncbi.nlm.nih.gov/33104287/>
28. Maddox R, Waa A, Henderson PN, Calma T, Kennedy M. Commercial Tobacco and Cancer. In: Garvey G, editor. Indigenous and Tribal Peoples and Cancer [Internet]. Cham: Springer Nature Switzerland; 2024 [cited 2024 Oct 15]. p. 171–5. Available from: https://doi.org/10.1007/978-3-031-56806-0_36
29. Closing the Gap. National Agreement on Closing the Gap [Internet]. Australian Government; 2020 [cited 2024 Aug 28]. Available from: <https://www.closingthegap.gov.au/sites/default/files/files/national-agreement-ctg.pdf>
30. Cancer Australia. Australian Cancer Plan | Cancer Australia [Internet]. c2024 [cited 2024 Jun 23]. Available from: <https://www.canceraustralia.gov.au/australian-cancer-plan>
31. National Aboriginal Community Controlled Health Organisation. Aboriginal and Torres Strait Islander Cancer Plan [Internet]. NACCHO; 2023 [cited 2024 Jun 23]. Available from: https://www.naccho.org.au/app/uploads/2024/02/NACCHO_CancerPlan_Oct2023_FA_online.pdf

32. Ahpra and National Boards. Australian Health Practitioner Regulation Agency. c2023 [cited 2024 Mar 28]. Aboriginal and Torres Strait Islander Health Strategy. Available from: <https://www.ahpra.gov.au/About-Ahpra/Aboriginal-and-Torres-Strait-Islander-Health-Strategy.aspx>
33. Williamson TJ, Rawl SM, Kale MS, Carter-Harris L. Lung Cancer Screening and Stigma: Do Smoking-related Differences in Perceived Lung Cancer Stigma Emerge Prior to Diagnosis? *Stigma Health* [Internet]. 2023 Nov [cited 2024 Oct 15];8(4). Available from: <https://pubmed.ncbi.nlm.nih.gov/38239631/>
34. Hamann HA, Ostroff JS, Marks EG, Gerber DE, Schiller JH, Lee SJC. Stigma among patients with lung cancer: a patient-reported measurement model. *Psychooncology* [Internet]. 2014 Jan;23(1):81–92. Available from: <https://doi.org/10.1002/pon.3371>
35. Lung Foundation Australia. The Next Breath: Accelerating Lung Cancer Reform in Australia [Internet]. Lung Foundation Australia; 2022 [cited 2024 Jun 23]. Available from: <https://lungfoundation.com.au/resources/the-next-breath-accelerating-lung-cancer-reform-in-australia/>
36. Shen MJ, Hamann HA, Thomas AJ, Ostroff JS. Association between patient-provider communication and lung cancer stigma. *Support Care Cancer* [Internet]. 2016 May [cited 2024 Oct 15];24(5):2093–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/26553030/>
37. Rankin NM, McWilliams A, Marshall HM. Lung cancer screening implementation: Complexities and priorities. *Respirology* [Internet]. 2020 [cited 2024 Feb 22];25(S2):5–23. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/resp.13963>
38. Kauczor HU, Baird AM, Blum TG, Bonomo L, Bostantzoglou C, Burghuber O, et al. ESR/ERS statement paper on lung cancer screening. *Eur Respir J* [Internet]. 2020 Feb;55(2):1900506. Available from: <https://erj.ersjournals.com/content/55/2/1900506>
39. Rose S, Paul C, Boyes A, Kelly B, Roach D. Stigma-related experiences in non-communicable respiratory diseases: A systematic review. *Chron Respir Dis* [Internet]. 2017 Aug [cited 2024 Jun 23];14(3):199–216. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5720230/>
40. Madawala S, Enticott J, Sturgiss E, Selamoglu M, Barton C. The impact of smoking status on anticipated stigma and experience of care among smokers and ex-smokers with chronic illness in general practice. *Chronic Illn* [Internet]. 2023 Sep;19(3):557–70. Available from: <https://doi.org/10.1177/17423953221101337>
41. Chambers SK, Dunn J, Occhipinti S, Hughes S, Baade P, Sinclair S, et al. A systematic review of the impact of stigma and nihilism on lung cancer outcomes. *BMC Cancer* [Internet]. 2012 May 20 [cited 2024 Mar 28];12(1):184. Available from: <https://doi.org/10.1186/1471-2407-12-184>
42. Quaipe SL, Marlow LAV, McEwen A, Janes SM, Wardle J. Attitudes towards lung cancer screening in socioeconomically deprived and heavy smoking communities: informing screening communication. *Health Expect* [Internet]. 2017 [cited 2024 Mar 26];20(4):563–73. Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1111/hex.12481>
43. Gould GS, Watt K, McEwen A, Cadet-James Y, Clough AR. Predictors of intentions to quit smoking in Aboriginal tobacco smokers of reproductive age in regional New South Wales (NSW), Australia: quantitative and qualitative findings of a cross-sectional survey. *BMJ Open* [Internet]. 2015 Mar 1 [cited 2024 Jun 23];5(3):e007020. Available from: <https://bmjopen.bmj.com/content/5/3/e007020>
44. Green M, Anderson K, Griffiths K, Garvey G, Cunningham J. Understanding Indigenous Australians' experiences of cancer care: stakeholders' views on what to measure and how to measure it. *BMC Health Serv Res* [Internet]. 2018 Dec 19 [cited 2024 Jun 23];18(1):982. Available from: <https://doi.org/10.1186/s12913-018-3780-8>
45. Maddox R, Kennedy M, Waa A, Drummond A, Hardy BJ, Soto C, et al. Clearing the Air: Conflicts of Interest and the Tobacco Industry's Impact on Indigenous Peoples. *Nicotine Tob Res Off J Soc Res Nicotine Tob* [Internet]. 2022 Apr 28;24(6):933–6. Available from: <https://doi.org/10.1093/ntr/ntab267>

46. Quaife SL, Vrinten C, Ruparel M, Janes SM, Beeken RJ, Waller J, et al. Smokers' interest in a lung cancer screening programme: a national survey in England. *BMC Cancer* [Internet]. 2018 May 2;18(1):497. Available from: <https://doi.org/10.1186/s12885-018-4430-6>
47. Goldstein E, Chokshi B, Melendez-Torres G, Rios A, Jelley M, Lewis-O'Connor A. Effectiveness of Trauma-Informed Care Implementation in Health Care Settings: Systematic Review of Reviews and Realist Synthesis. *Perm J* [Internet]. [cited 2024 Aug 28];28(1):135–50. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10940237/>
48. McFadden K, Rankin NM, Nickel B, Li T, Jennett CJ, Sharman AR, et al. Lung cancer screening program factors that influence psychosocial outcomes: A systematic review. *Psychooncology* [Internet]. 2024 Jan;33(1):e6252. Available from: <https://doi.org/10.1002/pon.6252>
49. Quaife SL, Janes SM, Brain KE. The person behind the nodule: a narrative review of the psychological impact of lung cancer screening. *Transl Lung Cancer Res* [Internet]. 2021 May;10(5):2427–40. Available from: <https://doi.org/10.21037/tlcr-20-1179>
50. Greenhalgh E, Scollo M, Winstanley M. Tobacco in Australia - Facts and issues [Internet]. 2024 [cited 2024 Jun 23]. Available from: https://www.tobaccoinustralia.org.au/homepage_module/homepagec_content/homepagec_main_content/home_content.html
51. The Royal Australian College of General Practitioners. Supporting smoking cessation: A guide for health professionals. [Internet]. East Melbourne, Vic: RACGP; 2019 [cited 2024 Mar 26]. (Second edition). Available from: <https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/diabetes/lifestyle-interventions-for-management-of-type-1/smoking-cessation>
52. Greenhalgh E, Jenkins S, Stillman S, Ford C. 7.1 Health and other benefits of quitting, in *Tobacco in Australia - Facts and issues* [Internet]. Tobacco in Australia; 2020 [cited 2024 Jun 23]. Available from: <https://www.tobaccoinustralia.org.au/chapter-7-cessation/7-1-health-and-other-benefits-of-quitting>
53. Australian Institute of Health and Welfare. Australian Institute of Health and Welfare. 2019 [cited 2024 Jun 23]. Burden of tobacco use in Australia: Australian Burden of Disease Study 2015, Related material. Available from: <https://www.aihw.gov.au/reports/burden-of-disease/burden-of-tobacco-use-in-australia/related-material>
54. Australian Government Department of Health and Aged Care. Australian Government Department of Health and Aged Care. Australian Government Department of Health and Aged Care; 2023 [cited 2024 Mar 28]. National Tobacco Strategy. Available from: <https://www.health.gov.au/our-work/national-tobacco-strategy>
55. Thomas DP, Davey ME, Briggs VL, Borland R, on behalf of the Talking About The Smokes project. Talking About The Smokes: summary and key findings. *Med J Aust* [Internet]. 2015 Jun 1 [cited 2024 Aug 23];202(10). Available from: <https://www.mja.com.au/journal/2015/202/10/talking-about-smokes-summary-and-key-findings>
56. Colonna E, Maddox R, Cohen R, Marmor A, Doery K, Thurber K, et al. Review of tobacco use among Aboriginal and Torres Strait Islander peoples. *Aust Indig Heal* [Internet]. 2020 Jun 4 [cited 2024 Mar 28];20(2). Available from: <https://healthbulletin.org.au/articles/review-of-tobacco-use-among-aboriginal-and-torres-strait-islander-peoples/>
57. Brady M. Health Inequalities: Historical and cultural roots of tobacco use among Aboriginal and Torres Strait Islander people. *Aust N Z J Public Health* [Internet]. 2002 Apr 1 [cited 2024 Mar 28];26(2):120–4. Available from: <https://www.sciencedirect.com/science/article/pii/S1326020023032168>
58. Cosh S, Hawkins K, Skaczkowski G, Copley D, Bowden J. Tobacco use among urban Aboriginal Australian young people: a qualitative study of reasons for smoking, barriers to cessation and motivators for smoking cessation. *Aust J Prim Health* [Internet]. 2015 Sep 28 [cited 2024 Mar 28];21(3):334–41. Available from: <https://www.publish.csiro.au/py/PY13157>
59. van der Sterren A, Greenhalgh E, Knoche D, Winstanley M. 8.9 Attitudes to and beliefs about smoking among Aboriginal and Torres Strait Islander peoples. [Internet]. Tobacco in Australia; 2016 [cited 2024 Jun 23]. Available from: <https://www.tobaccoinustralia.org.au/chapter-8-aptsi/8-9-attitudes-to-and-beliefs-about-smoking>

60. Colonna E, Heris CL, Barrett EM, Wells S, Maddox R. Aboriginal and Torres Strait Islander peoples' Quitline use and the Tackling Indigenous Smoking program - Online Early | PHRP. Public Health Res Pr [Internet]. 2024 Mar 5 [cited 2024 Jun 23]; Available from: <https://www.phrp.com.au/issues/online-early/quitline-and-tackling-indigenous-smoking-program/>
61. Martin K, Dono J, Rigney N, Rayner J, Sparrow A, Miller C, et al. Barriers and facilitators for health professionals referring Aboriginal and Torres Strait Islander tobacco smokers to the Quitline. Aust N Z J Public Health [Internet]. 2017 Dec;41(6):631–4. Available from: <https://doi.org/10.1111/1753-6405.12727>
62. Carter-Harris L, Gould MK. Multilevel Barriers to the Successful Implementation of Lung Cancer Screening: Why Does It Have to Be So Hard? Ann Am Thorac Soc [Internet]. 2017 Aug [cited 2024 Jun 23];14(8):1261–5. Available from: <https://www.atsjournals.org/doi/10.1513/AnnalsATS.201703-204PS>
63. Núñez ER, Fukunaga MI, Stevens GA, Yang JK, Reid SE, Spiegel JL, et al. Review of Interventions That Improve Uptake of Lung Cancer Screening: A Cataloging of Strategies That Have Been Shown to Work (or Not). CHEST [Internet]. 2024 May 24 [cited 2024 Jun 21];0(0). Available from: [https://journal.chestnet.org/article/S0012-3692\(24\)00654-8/abstract](https://journal.chestnet.org/article/S0012-3692(24)00654-8/abstract)
64. Williams LB, Looney SW, Joshua T, McCall A, Tingen MS. Promoting Community Awareness of Lung Cancer Screening Among Disparate Populations: Results of the cancer-Community Awareness Access Research and Education Project. Cancer Nurs [Internet]. 2021 Apr 1;44(2):89–97. Available from: <https://doi.org/10.1097/ncc.0000000000000748>
65. Cardarelli R, Roper KL, Cardarelli K, Feltner FJ, Prater S, Ledford KM, et al. Identifying Community Perspectives for a Lung Cancer Screening Awareness Campaign in Appalachia Kentucky: The Terminate Lung Cancer (TLC) Study. J Cancer Educ Off J Am Assoc Cancer Educ [Internet]. 2017 Mar;32(1):125–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/26411308/>
66. Quaife SL, Ruparel M, Dickson JL, Beeken RJ, McEwen A, Baldwin DR, et al. Lung Screen Uptake Trial (LSUT): Randomized Controlled Clinical Trial Testing Targeted Invitation Materials. Am J Respir Crit Care Med [Internet]. 2020 Apr 15;201(8):965–75. Available from: <https://pubmed.ncbi.nlm.nih.gov/31825647/>
67. Hudson JN, Quinn GP, Wilson LE, Simmons VN. Evaluation of Promotional Materials To Promote Low-Dose Computed Tomography (LDCT) Screening to High-Risk Consumers and Health Care Providers. J Cancer Educ Off J Am Assoc Cancer Educ [Internet]. 2018 Oct;33(5):1043–51. Available from: <https://pubmed.ncbi.nlm.nih.gov/28285419/>
68. Seale H, Harris-Roxas B, Heywood A, Abdi I, Mahimbo A, Chauhan A, et al. The role of community leaders and other information intermediaries during the COVID-19 pandemic: Insights from the multicultural sector in Australia. Humanit Soc Sci Commun [Internet]. 2022 May 17 [cited 2024 Oct 16];9(1):1–7. Available from: <https://www.nature.com/articles/s41599-022-01196-3>
69. Li J, Chung S, Wei EK, Luft HS. New recommendation and coverage of low-dose computed tomography for lung cancer screening: uptake has increased but is still low. BMC Health Serv Res [Internet]. 2018 Jul 5;18(1):525. Available from: <https://pubmed.ncbi.nlm.nih.gov/29976189/>
70. Dodd RH, Sharman AR, McGregor D, Stone E, Donnelly C, Lourenco RDA, et al. Education messages and strategies to inform the public, potential screening candidates and healthcare providers about lung cancer screening: A systematic review. Prev Med [Internet]. 2023 Apr;169:107459. Available from: <https://pubmed.ncbi.nlm.nih.gov/36854365/>
71. Services Australia, Australian Government. Who can claim telehealth services under MBS or DVA - Health professionals - Services Australia [Internet]. 2024 [cited 2024 Aug 28]. Available from: <https://www.servicesaustralia.gov.au/who-can-claim-telehealth-services-under-mbs-or-dva?context=20>
72. Cancer Australia. Investigating symptoms of lung cancer: a guide for all health professionals | Cancer Australia [Internet]. 2020 [cited 2024 Jun 23]. Available from: <https://www.canceraustralia.gov.au/ISLGuide>
73. Cancer Council. Optimal care pathway for people with lung cancer - second edition [Internet]. 2021 [cited 2024 Jun 23]. Available from: <https://www.cancer.org.au/health-professionals/optimal-cancer-care-pathways>
74. Cancer Australia. Optimal Care Pathway for Aboriginal and Torres Strait Islander people with cancer | Cancer Australia [Internet]. 2018 [cited 2024 Jun 23]. Available from: <https://www.canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/optimal-care-pathway-aboriginal-and-torres-strait-islander-people-cancer>

75. Young RP, Ward RC, Scott RJ, Gamble GD, Silvestri G. Airflow limitation and mortality during cancer screening in the National Lung Screening Trial: why quantifying airflow limitation matters. *Thorax*. 2023 Jul;78(7):690–7.
76. ECOG-ACRIN cancer research group. ECOG-ACRIN Cancer Research Group. c2022 [cited 2024 Jun 23]. ECOG Performance Status Scale. Available from: <https://ecog-acrin.org/resources/ecog-performance-status/>
77. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. *Lancet Oncol*. 2019 Apr;20(4):494–503.
78. Agency for Clinical Innovation. Consumer enablement - A clinician's guide. 2018 [cited 2024 Oct 30]. Consumer enablement guide. Available from: <https://aci.health.nsw.gov.au/projects/consumer-enablement>
79. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, et al. Shared decision making: a model for clinical practice. *J Gen Intern Med*. 2012 Oct;27(10):1361–7.
80. Consumers Health Forum of Australia. Patient Activation in Australians with Chronic Illness Project | Consumers Health Forum of Australia [Internet]. 2020 [cited 2024 Aug 27]. Available from: <https://chf.org.au/projects/patient-activation-australians-chronic-illness-project>
81. Department of Health and Aged Care. Health Insurance Act 1973 [Internet]. Australian Government; 2024 [cited 2024 Oct 9]. Available from: <https://www.legislation.gov.au/C2004A00101/latest>
82. Department of Health and Aged Care. MBS Online | Medicare Benefits Schedule. [cited 2024 Oct 15]. Note IN.0.6 | Medicare Benefits Schedule. Available from: <https://www9.health.gov.au/mbs/fullDisplay.cfm?type=note&q=IN.0.6&qt=noteID>
83. The Royal Australian and New Zealand College of Radiologists. Standards of Practice for Clinical Radiology [Internet]. Sydney, Australia: RANZCR; 2020 [cited 2024 Mar 28]. Available from: <https://www.ranzcr.com/college/document-library/ranzcr-standards-of-practice-for-diagnostic-and-interventional-radiology>
84. Cancer Council Victoria, Department of Health Victoria. Optimal care pathway for people with lung cancer [Internet]. Melbourne, Victoria: Cancer Council Victoria; 2021. Report No.: 2nd edn. Available from: <https://www.cancer.org.au/assets/pdf/lung-cancer-optimal-cancer-care-pathway>
85. Rami-Porta R, Nishimura KK, Giroux DJ, Detterbeck F, Cardillo G, Edwards JG, et al. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer. *J Thorac Oncol* [Internet]. 2024 Jul 1 [cited 2024 Oct 15];19(7):1007–27. Available from: [https://www.jto.org/article/S1556-0864\(24\)00079-0/fulltext](https://www.jto.org/article/S1556-0864(24)00079-0/fulltext)
86. Bui KT, Liang R, Kiely BE, Brown C, Dhillion HM, Blinman P. Scanxiety: a scoping review about scan-associated anxiety. *BMJ Open* [Internet]. 2021 May 1 [cited 2024 Jun 21];11(5):e043215. Available from: <https://bmjopen.bmj.com/content/11/5/e043215>
87. International Association for the Study of Lung Cancer. IASLC. 2021 [cited 2024 Mar 21]. IASLC Language Guide. Available from: <https://www.iaslc.org/IASLCLanguageGuide>
88. Witt A de, Matthews V, Bailie R, Garvey G, Valery PC, Adams J, et al. Communication, Collaboration and Care Coordination: The Three-Point Guide to Cancer Care Provision for Aboriginal and Torres Strait Islander Australians. 2020 Jun 8 [cited 2024 Jun 23];20(2):10. Available from: <https://ijic.org/articles/10.5334/ijic.5456>
89. Cancer Australia. National Aboriginal and Torres Strait Islander Cancer Framework [Internet]. 2015 [cited 2024 Jun 23]. Available from: <https://www.canceraustralia.gov.au/publications-and-resources/cancer-australia-publications/national-aboriginal-and-torres-strait-islander-cancer-framework>
90. Cancer Council. Information for Aboriginal and Torres Strait Islander people [Internet]. [cited 2024 Jun 23]. Available from: <https://www.cancer.org.au/support-and-services/information-for-aboriginal-and-torres-strait-islanders>

91. Cultural Capability Team. Communicating effectively with Aboriginal and Torres Strait Islander people [Internet]. Queensland Health; 2015 [cited 2024 Jun 23]. Available from: https://www.health.qld.gov.au/_data/assets/pdf_file/0021/151923/communicating.pdf
92. RACGP. Standards for general practices (5th edition) [Internet]. Royal Australian College of General Practitioners; 2023 [cited 2024 Dec 9]. Available from: <https://www.racgp.org.au/running-a-practice/practice-standards/standards-5th-edition/standards-for-general-practices-5th-ed/table-of-contents>
93. Penha D, Pinto E, Monaghan C, Hochhegger B, Marchiori E, Taborda-Barata L, et al. Incidental findings on lung cancer screening: pictorial essay and systematic checklist. *J Bras Pneumol* [Internet]. 2022 [cited 2024 Mar 28];48(1). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836644/>
94. Hoffmann TC, Légaré F, Simmons MB, McNamara K, McCaffery K, Trevena LJ, et al. Shared decision making: what do clinicians need to know and why should they bother? *Med J Aust* [Internet]. 2014 Jul 7;201(1):35–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/25358570/>
95. Australian Commission on Safety and Quality in Health Care. Shared decision making | Australian Commission on Safety and Quality in Health Care [Internet]. c2024 [cited 2024 Mar 27]. Available from: <https://www.safetyandquality.gov.au/our-work/partnering-consumers/shared-decision-making>
96. Huber RM, Cavic M, Balata H, Kitts AB, Field JK, Henschke C, et al. From the IASLC Early Detection and Screening Committee Terminology Issues in Screening and Early Detection of Lung Cancer - IASLC Early Detection and Screening Committee Expert Group Recommendations. *J Thorac Oncol Off Publ Int Assoc Study Lung Cancer* [Internet]. 2024 Aug 2;S1556-0864(24)00747-0. Available from: <https://pubmed.ncbi.nlm.nih.gov/39098452/>

DRAFT